Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically, ~~and posted on its corporate Web site, if any,~~ every Interactive Data File required to be submitted ~~and posted~~ pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit ~~and post~~ such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. ~~(Check one)~~:

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November ~~3, 2017,~~1, 2021, the number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was ~~10,516,406.~~

In this Quarterly Report on Form 10-Q, “we,” “our,” “us,” “Eiger,” and “the Company” refer to Eiger ~~Biopharmaceuticals,~~BioPharmaceuticals, Inc., Eiger ~~Eiger Biopharmaceuticals,~~BioPharmaceuticals, the Eiger logo and other trade names, trademarks or service marks of Eiger are the property of Eiger ~~Biopharmaceuticals,~~BioPharmaceuticals, Inc. This Quarterly Report on Form 10-Q contains references to our trademarks and to trademarks belonging to other entities. Trade names, trademarks and service marks of other companies appearing in this Quarterly Report on Form 10-Q are the property of their respective holders. We do not intend our use or display of other companies’ trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by any other companies.

	September 30,			December 31,			September 30,			December 31,
	2017			2016			2021			2020
	(Unaudited)						(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	13,078		$	27,756		$	49,255		$	28,864
Marketable securities		19,264			32,180
Short-term debt securities								36,051			99,976
Accounts receivable, net								2,762			—
Inventories								2,621			93
Prepaid expenses and other current assets		783			581			8,397			8,873
Total current assets		33,125			60,517			99,086			137,806
Long-term debt securities								35,093			—
Property and equipment, net		90			76			581			709
Operating lease right-of-use assets								777			1,176
Other assets		66			143			4,740			3,903
Total assets	$	33,281		$	60,736		$	140,277		$	143,594
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	4,167		$	2,639		$	6,753		$	4,640
Accrued liabilities		1,566			2,649			11,579			11,405
Current portion of operating lease liabilities								608			582
Current portion of long-term debt, net								3,072			—
Total current liabilities		5,733			5,288			22,012			16,627
Long term debt, net		14,993			14,727
Long-term debt, net								28,524			31,194
Operating lease liabilities								276			738
Total liabilities		20,726			20,015			50,812			48,559
Stockholders’ equity:
Common stock		8			8			34			34
Additional paid-in capital		120,462			117,086			408,079			401,509
Accumulated other comprehensive loss		(2	)		(15	)
Accumulated other comprehensive income (loss)								1			(8	)
Accumulated deficit		(107,913	)		(76,358	)		(318,649	)		(306,500	)
Total stockholders’ equity		12,555			40,721			89,465			95,035
Total liabilities and stockholders’ equity	$	33,281		$	60,736		$	140,277		$	143,594

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

	Three Months Ended						Nine Months Ended						Three Months Ended						Nine Months Ended
	September 30,						September 30,						September 30,						September 30,
	2017			2016			2017			2016			2021			2020			2021			2020
Operating expenses:
Product revenue, net													$	3,039		$	—		$	8,782		$	—
Costs and operating expenses:
Cost of sales														318			—			641			—
Research and development	$	6,145		$	8,072		$	21,740		$	23,637			18,106			9,810			46,250			29,045
General and administrative		2,727			3,264			9,195			9,574
Total operating expenses		8,872			11,336			30,935			33,211
Selling, general and administrative														6,466			5,027			17,916			15,141
Total costs and operating expenses														24,890			14,837			64,807			44,186
Loss from operations		(8,872	)		(11,336	)		(30,935	)		(33,211	)		(21,851	)		(14,837	)		(56,025	)		(44,186	)
Interest expense		(388	)		—			(1,129	)		(685	)		(894	)		(906	)		(2,659	)		(2,681	)
Interest income		98			—			321			—			35			76			119			629
Other income (expense), net		(8	)		(34	)		188			(423	)		503			(13	)		46,462			(7	)
Loss before provision for income taxes														(22,207	)		(15,680	)		(12,103	)		(46,245	)
Provision for income taxes														16			—			46			—
Net loss	$	(9,170	)	$	(11,370	)	$	(31,555	)	$	(34,319	)	$	(22,223	)	$	(15,680	)	$	(12,149	)	$	(46,245	)
Net loss per common share, basic and diluted	$	(1.10	)	$	(1.49	)	$	(3.77	)	$	(6.58	)
Weighted-average common shares outstanding, basic and diluted		8,372,934			7,622,963			8,366,880			5,218,099
Net loss per common share:
Basic and diluted													$	(0.65	)	$	(0.52	)	$	(0.36	)	$	(1.74	)
Weighted-average common shares outstanding:
Basic and diluted														33,946,559			29,879,135			33,922,080			26,639,201

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Nine Months Ended

September 30,

2017

2016

Operating activities

Net loss

$
(31,555
)

$
(34,319
)
Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

30

15

Amortization of premiums on marketable securities

(63
)

—

Non-cash interest expense

266

685

Stock-based compensation

3,223

1,751

Gain on intellectual property sale

(200
)

—

Change in fair value of obligation to issue shares to Eiccose

—

204

Change in fair value of warrant liability

—

165

Issuance of common stock in connection with a license agreement

—

3,172

Change in operating assets and liabilities:

Prepaid expenses and other current assets

(202
)

(5
)
Other non-current assets

77

(88
)
Accounts payable

1,528

2,135

Accrued and other liabilities

(1,083
)

(547
)
Net cash used in operating activities

(27,979
)

(26,832
)
Investing activities

Purchase of marketable securities

(22,533
)

—

Proceeds from maturities of marketable securities

35,525

—

Proceeds from intellectual property sale

200

—

Proceeds from merger transaction

—

28,018

Purchase of property and equipment

(44
)

(53
)
Net cash provided by investing activities

13,148

27,965

Financing activities

Proceeds from issuance of common stock upon private placement, net of issuance cost

—

32,108

Proceeds from issuance of common stock upon public offering, net of issuance cost

—

18,229

Proceeds from issuance of common stock upon ESPP purchase

142

—

Proceeds from issuance of common stock upon options exercises

11

39

Proceeds from issuance of common stock upon warrants exercises

—

7

Net cash provided by financing activities

153

50,383

Net (decrease) increase in cash and cash equivalents

(14,678
)

51,516

Cash and cash equivalents at beginning of period

27,756

4,778

Cash and cash equivalents at end of period

$
13,078

$
56,294

Supplemental disclosures of non-cash investing and financing information:

Non-cash activities:

Conversion of warrant liability to common stock upon private placement

$
—

$
1,050

Issuance of common stock in connection with a license agreement

$
—

$
3,172

Issuance of common stock to Eiccose upon private placement

$
—

$
1,661

Non-cash net liabilities assumed in reverse merger

$
—

$
671

Conversion of convertible promissory note to common stock upon private
placement

$
—

$
6,129

Conversion of preferred stock to common stock upon reverse merger

$
—

$
22,567

	Common Stock				Additional Paid-In		Accumulated Other Comprehensive			Accumulated			Total Stockholders’
	Shares		Amount		Capital		Income (Loss)			Deficit			Equity
Balance at December 31, 2020		33,878,486	$	34	$	401,509	$	(8	)	$	(306,500	)	$	95,035
Issuance of common stock upon exercise of stock options		19,150		—		166		—			—			166
Vesting of common stock issued under Product Development Agreement		—		—		53		—			—			53
Issuance of common stock upon ESPP purchase		19,928		—		136		—			—			136
Issuance of common stock upon release of restricted stock units		33,750		—		—		—			—			—
Stock-based compensation expense		—		—		1,549		—			—			1,549
Unrealized gain on available-for-sale debt securities, net		—		—		—		3			—			3
Net income		—		—		—		—			29,248			29,248
Balance at March 31, 2021		33,951,314		34		403,413		(5	)		(277,252	)		126,190
Vesting of common stock issued under Product Development Agreement		—		—		52		—			—			52
Stock-based compensation expense		—		—		2,058		—			—			2,058
Unrealized loss on available-for-sale debt securities, net		—		—		—		(1	)		—			(1	)
Net loss		—		—		—		—			(19,174	)		(19,174	)
Balance at June 30, 2021		33,951,314		34		405,523		(6	)		(296,426	)		109,125
Vesting of common stock issued under Product Development Agreement		—		—		62		—			—			62
Issuance of common stock upon exercise of stock options		6,795		—		43		—			—			43
Issuance of common stock upon ESPP purchase		17,691		—		121		—			—			121
Stock-based compensation expense		—		—		2,330		—			—			2,330
Unrealized gain on available-for-sale debt securities, net		—		—		—		7			—			7
Net loss		—		—		—		—			(22,223	)		(22,223	)
Balance at September 30, 2021		33,975,800		34		408,079		1			(318,649	)		89,465

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

	Common Stock				Additional Paid-In		Accumulated Other Comprehensive			Accumulated			Total Stockholders’
	Shares		Amount		Capital		Income (Loss)			Deficit			Equity
Balance at December 31, 2019		24,523,381	$	24	$	297,863	$	42		$	(241,449	)	$	56,480
Issuance of common stock upon exercise of stock options		2,895		—		30		—			—			30
Vesting of common stock issued under Product Development Agreement		—		—		53		—			—			53
Issuance of common stock upon ESPP purchase		11,332		—		83		—			—			83
Issuance of common stock upon offering at-the -market, net of issuance costs of $221		32,751		—		191		—			—			191
Stock-based compensation expense		—		—		1,629		—			—			1,629
Unrealized loss on available-for-sale debt securities, net		—		—		—		(6	)		—			(6	)
Net loss		—		—		—		—			(15,239	)		(15,239	)
Balance at March 31, 2020		24,570,359		24		299,849		36			(256,688	)		43,221
Issuance of common stock upon offering at-the -market, net of issuance costs of $786		2,612,476		3		28,577		—			—			28,580
Issuance of common stock upon exercise of stock options		58,805		—		490		—			—			490
Vesting of common stock issued under Product Development Agreement		—		—		55		—			—			55
Stock-based compensation expense		—		—		1,462		—			—			1,462
Unrealized gain on available-for-sale debt securities, net		—		—		—		9			—			9
Net loss		—		—		—		—			(15,326	)		(15,326	)
Balance at June 30, 2020		27,241,640	$	27	$	330,433	$	45		$	(272,014	)	$	58,491
Vesting of common stock issued under Product Development Agreement		—		—		56		—			—			56
Issuance of common stock upon ESPP purchase		14,313		—		103		—			—			103
Issuance of common stock upon offering at-the -market, net of issuance costs of $1,575		4,660,086		5		48,559		—			—			48,564
Stock-based compensation expense		—		—		1,445		—			—			1,445
Unrealized loss on available-for-sale debt securities, net		—		—		—		(29	)		—			(29	)
Net loss		—		—		—		—			(15,680	)		(15,680	)
Balance at September 30, 2020		31,916,039		32		380,596		16			(287,694	)		92,950

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

	Nine Months Ended
	September 30,
	2021			2020
Operating activities
Net loss	$	(12,149	)	$	(46,245	)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain from sale of priority review voucher		(46,493	)		—
Income related to asset purchase agreement		(281	)		—
Depreciation and amortization		203			112
Amortization of debt securities premiums and discounts		658			(33	)
Non-cash interest expense		577			593
Amortization of operating lease right-of-use assets		399			354
Common stock issued under Product Development Agreement		167			164
Stock-based compensation		5,937			4,536
Change in operating assets and liabilities:
Accounts receivable		(2,762	)		—
Inventories		(2,528	)		—
Prepaid expenses and other current assets		493			(4,418	)
Other assets		(837	)		(1,270	)
Accounts payable		2,218			1,836
Accrued liabilities		257			(2,893	)
Operating lease liabilities		(436	)		(406	)
Net cash used in operating activities		(54,577	)		(47,670	)
Investing activities
Purchase of debt securities available-for-sale		(71,447	)		(92,480	)
Proceeds from maturities of debt securities available-for-sale		99,630			74,767
Proceeds related to asset purchase agreement		281			—
Proceeds from sale of priority review voucher		95,000			—
Payments related to priority review voucher		(48,507	)		—
Purchase of property and equipment		(92	)		(107	)
Net cash provided by (used in) investing activities		74,865			(17,820	)
Financing activities
Issuance of common stock upon offering at-the-market, net of issuance costs		—			77,404
Proceeds from issuance of common stock upon stock option exercises		209			520
Proceeds from issuance of common stock upon ESPP purchase		277			186
Payment of debt issuance costs		(175	)		—
Payment of deferred offering costs		(208	)		—
Net cash provided by financing activities		103			78,110
Net increase in cash and cash equivalents		20,391			12,620
Cash and cash equivalents at beginning of period		28,864			39,373
Cash and cash equivalents at end of period	$	49,255		$	51,993

Supplemental disclosure of cash flow information:
Interest paid	$	2,082		$	2,089

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Eiger BioPharmaceuticals, Inc. (the ~~“Company”)~~Company or Eiger) was incorporated in the State of Delaware on November 6, 2008. Eiger is a ~~clinical-stage~~commercial-stage biopharmaceutical company ~~committed~~focused on the development and commercialization of well-characterized drugs and biologics for serious rare and ultra-rare diseases with high unmet medical needs. Eiger has reported positive proof-of-concept clinical results across all of our programs. All five of our rare disease programs have FDA Breakthrough Therapy Designation.

Eiger’s lead clinical programs are focused on the development of complementary, foundational treatments for Hepatitis Delta Virus (HDV), the most severe form of viral hepatitis, for which there is currently no FDA-approved therapy. Lonafarnib is a first-in-class oral farnesylation inhibitor and peginterferon lambda is a first-in-class, type III, well-tolerated interferon. Both lonafarnib and peginterferon lambda are in global Phase 3 trials.

The FDA approved the Company’s first commercial product, Zokinvy^® (lonafarnib) to ~~bringing to market novel products~~reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria), and for ~~the~~ treatment of ~~orphan diseases.~~ processing-deficient progeroid laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation, or homozygous or compound heterozygous ZMPSTE24 mutations, ultra-rare and rapidly fatal genetic conditions of accelerated aging in children, on November 20, 2020. Eiger’s Marketing Authorization Application (MAA) is under review with the European Medicines Agency (EMA) with an opinion from the Committee for Medicinal Products for Human Use (CHMP) expected around the end of 2021.

The Company ~~has built~~is also developing avexitide, a ~~diverse portfolio of~~ well-characterized ~~product candidates with the potential to address diseases~~peptide, as a treatment for post-bariatric hypoglycemia (PBH), a debilitating and potentially life-threatening condition for which ~~the unmet medical need~~there is ~~high, the biology~~currently no approved therapy, and as a treatment for ~~treatment is clear, and for which~~congenital hyperinsulinism (HI), an ~~effective therapy is urgently needed.~~ ultra-rare pediatric metabolic disorder.

The Company’s principal operations are based in Palo Alto, California and it operates in ~~one~~1 segment.

As of September 30, ~~2017,~~2021, the Company had ~~$13.1~~$85.3 million of cash, cash equivalents and short-term securities, comprised of $49.3 million of cash and cash equivalents ~~$19.3~~and $36.0 million of short-term ~~marketable~~debt securities available-for-sale. As of September 30, 2021, the Company also had $35.1 million of long-term debt securities available-for-sale. The Company had an accumulated deficit of ~~$107.9~~$318.6 million and negative cash flows from operating ~~activities.~~activities as of September 30, 2021. As the Company continues to incur losses, its transition to profitability will depend on the successful development, approval, and commercialization of product candidates and on the achievement of sufficient revenues to support its cost structure. The Company ~~expects~~may never achieve profitability, and until it does, the Company will need to continue to ~~incur losses for the next several years.~~

On October 31, 2017, the Company issued 2,132,961 shares of common stock pursuant to an underwriting agreement with BTIG, LLC at a public offering price of $10.00 per share, for gross proceeds of $21,329,610, which resulted in approximately $19.5 million of net proceeds to the Company after deducting underwriting fees and offering expenses. See Note11.raise additional capital.

Management believes that the currently available resources will be sufficient to fund its planned operations for at least the next 12 months following the issuance date of these ~~unaudited~~ condensed consolidated financial statements.

However, if the Company’s anticipated operating results are not achieved in future periods, the Company believes that planned expenditures may need to be reduced or it would be required to raise funding in order to fund the operations. Additionally, the Company’s ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic.

The unaudited ~~condensed~~ consolidated financial statements include the accounts of Eiger BioPharmaceuticals, Inc. and its wholly owned subsidiaries, EBPI Merger Inc., EB Pharma LLC, ~~and~~ Eiger BioPharmaceuticals Europe Limited, and EigerBio Europe Limited, have been prepared in accordance with accounting principles generally accepted in the United States of America, ~~(“U.S. GAAP”)~~(U.S. GAAP) and ~~following~~follow the requirements of the Securities and Exchange Commission (the ~~“SEC”)~~SEC) for ~~interim~~annual reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company’s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company’s financial information. These interim results are not necessarily indicative of the results to be expected for the year ending December 31, 2017 or for any other interim period or for any other future year. The balance sheet as of December 31, 2016, has been derived from audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete financial statements. All intercompany balances and transactions have been eliminated in consolidation.

Certain items on the unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto contained in the Company’s Annual Report on Form 10-K for thebalance sheet have been reclassified to conform to current year ~~ended December 31, 2016, filed with the Securities and Exchange Commission on March 23, 2017.~~presentation. Such items were not material.

The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its ~~estimates, including those related to clinical trial accrued liabilities, stock-based compensation and income taxes.~~estimates. The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.

Short-term ~~marketable~~ securities consist of debt securities classified as available-for-sale and have maturities greater than 90 days, but less than 365 days from the date of acquisition. Long-term securities consist of debt securities classified as available-for-sale and have maturities greater than 365 days from the date of acquisition. All short-term ~~marketable~~and long-term securities are carried at fair value based upon quoted market prices. Unrealized gains and losses on available-for-sale securities are excluded from earnings and are reported as a component of accumulated other comprehensive loss. The cost of available-for-sale securities sold is based on the specific-identification method. Realized gains and losses on the sale of ~~marketable~~debt securities are determined using the specific-identification method and recorded in other ~~expense,~~income, net on the accompanying unaudited condensed consolidated statements of operations.

Accounts receivable represent amounts billed to the Company’s customers, net of an allowance for doubtful accounts. Trade accounts receivable are recorded at invoiced amounts and do not bear interest. The expectation of collectability is based on a review of credit profiles of customers, contractual terms and conditions, current economic trends, and historical payment experience. The Company regularly reviews the adequacy of the allowance for doubtful accounts by considering the age of each outstanding invoice and the collection history of each customer to determine the appropriate amount of allowance for doubtful accounts.

The Company had 0 allowance as of September 30, 2021 and December 31, 2020. The Company had 0 bad debt expense for the three and nine months ended September 30, 2021 and 2020.

Inventories are stated at the lower of cost, determined based on actual costs, or estimated net realizable value, on a first-in, first-out basis. Inventories consist of raw materials, work-in-process and finished goods.

Prior to regulatory approval of the Company’s product candidates, expenses incurred to manufacture drug products are recorded as research and development expense. The Company begins capitalizing these expenses as inventory upon regulatory approval.

The Company periodically assesses the recoverability of its inventory and reduces the carrying value of the inventory when items are determined to be obsolete, defective or in excess of forecasted sales requirements. Inventory write-downs for excess, defective, and obsolete inventory are recorded as a cost of sales. There have been 0 write-downs of inventories for the periods presented.

The Company recognizes revenue upon transfer of control of promised products to customers in an amount that reflects the consideration it expects to receive in exchange for those products.To determine revenue recognition for contracts with customers, the Company performs the following five-step approach: (i) identify the contract, or contracts, with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the performance obligation is satisfied. The five-step model is only applied to contracts when it is probable that the Company will collect substantially all of the consideration it is entitled to in exchange for the goods transferred to the customer.

The Company’s product revenue consists of sales of Zokinvy, which received FDA approval in November 2020 and was launched commercially in the United States in January 2021. Prior to 2021, the Company had no product revenue. The Company sells Zokinvy to a specialty pharmacy provider (the Customer) that subsequently dispenses the product directly to patients. As all sales of Zokinvy are currently in the United States, and the Company only has one customer, the Company discloses revenue on a total basis without further disaggregation. Additionally, the Company does not have any contract assets or liabilities, other than accounts receivable, related to its product revenue.

The Company recognizes product revenue when the Customer obtains control of its product, which occurs at a point in time, typically upon delivery to the Customer as the delivery of the product is the Company’s only performance obligation. Shipping and handling activities are fulfillment activities rather than a separate performance obligation and are recorded in cost of sales.

Product revenue is recorded at the net sales price (transaction price), which includes estimates of variable consideration resulting from rebates, prompt payment discounts, co-payment assistance, and returns. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available. The amount of variable consideration may be constrained and is included in the transaction price only to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. Product revenue is recorded after considering the impact of the following variable consideration amounts along with the constraint at the time of revenue recognition:

Rebates: The Company’s products are subject to government mandated rebates for Medicaid Drug Rebate Program, Medicare Part D Prescription Drug Benefit Program, and other government health care programs in the United States. Rebate amounts are based upon contractual agreements or legal requirements with public sector benefit providers. The Company uses the expected-value method for estimating these rebates based on statutory discount rates and expected utilization. The expected utilization of rebates is estimated based on expected coverage of identified patients. Estimates for these rebates are adjusted quarterly to reflect the most recent information. The Company records an accrued liability for unpaid rebates related to products for which control has been transferred to the Customer.

Prompt payment discounts: The Company provides a discount to the Customer if it pays for purchases within 30 days. The Company expects that its Customer will earn prompt payment discounts and uses the most likely amount method for estimating such discounts. As a result, when revenues are recognized, the Company deducts the full amount of the prompt payment discounts from total product revenues and record these discounts as a reduction of accounts receivable.

Co-payment assistance: The Company provides co-payment assistance to patients who have commercial insurance and meet certain eligibility requirements. The Company uses the expected-value method for estimating co-payment assistance based on estimates of program redemption using data provided by third-party administrators. Estimates for the co-payment assistance are adjusted quarterly to reflect actual experience. The Company records an accrued liability for unredeemed co-payment assistance related to products for which control has been transferred to the Customer.

Product returns: The Company offers limited product return rights and generally allows for the return of product that is damaged or defective, or within a few months prior to and up to a few months after the product expiration date. The Company considers several factors in the estimation of potential product returns, including expiration dates of the product shipped, the limited product return rights, third-party data in monitoring channel inventory levels, shelf life of the product, and other relevant factors.

Cost of sales consists primarily of direct and indirect costs related to the manufacturing of Zokinvy for commercial sale, including third-party manufacturing costs, packaging services, freight, storage costs, and write down of inventories. Costs incurred prior to FDA approval in November 2020 were previously recorded as research and development expense in the condensed consolidated statements of operations.

The Company accrues for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical and clinical studies, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued liabilities in the ~~unaudited condensed~~ consolidated balance sheets and within research and development ~~expense~~expenses in the ~~unaudited condensed~~ consolidated statements of operations. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers. The Company makes judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities.

~~Basic net loss per share~~The Company has a real estate lease for its office space in Palo Alto, California. The Company determines the initial classification and measurement of ~~common stock is calculated by dividing~~its right-of-use assets (ROU assets) and lease liabilities at the ~~net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Since~~lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company ~~was~~is reasonably assured to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a ~~loss position~~similar economic environment.

Rent expense for ~~all periods presented, diluted net loss per share~~operating leases is recognized on a straight-line basis, unless the ~~same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would~~operating lease ROU assets have been ~~anti-dilutive.~~impaired, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease ROU assets on a straight-line basis over the remaining lease term with rent expense still included in selling, general and administrative expenses in the condensed consolidated statements of operations.

The ~~Weighted-average common shares outstanding for~~Company has elected the ~~three~~practical expedient to not separate lease and ~~nine months periods ended September 30, 2016,~~non-lease components. The Company’s non-lease components are ~~impacted by the weighted effect of the conversion or issuance of 6,668,045 common shares~~primarily related to property maintenance and insurance, which varies based on future outcomes, and thus is recognized in ~~conjunction with the closing of the Merger Agreement on March 22, 2016.~~selling, general and administrative expenses when incurred.

The following table sets forth the outstanding potentially dilutive securities which have been excluded in the calculation of diluted net loss per share because including such securities would be anti-dilutive (in common stock equivalent shares):

In ~~February~~June 2016, the FASB issued ASU ~~2016-02,~~ ~~Leases~~No. 2016-13, Financial Instruments—Credit Losses (Topic ~~842),~~ ~~which requires lessees to recognize most leases on their balance sheet.~~326). The standard ~~requires use of~~changes how entities will measure credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. Financial assets measured at amortized cost will be presented at the ~~modified retrospective transition method, with elective relief,~~net amount expected to be collected by using an allowance for credit losses. In April 2019, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326, Financial Instruments – Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, which ~~requires application~~clarifies and corrects certain unintended applications of the guidance contained in each of the amended Topics. Additionally, in May 2019, the FASB issued ASU No. 2019-05, Financial Instruments – Credit Losses (Topic 326), which provides an option to irrevocably elect to measure certain individual financial assets at fair value instead of amortized cost. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842), whichdefers the effective date for ~~all periods presented. The new standard will be effective~~ASU No. 2016-13 for smaller reporting companies to fiscal years beginning after December 15, ~~2018. Early adoption is permitted.~~ 2022, including interim periods within those fiscal years. The Company is ~~currently in the process of~~ evaluating the impact ~~that~~of the ~~standard will have~~guidance on its consolidated financial statements.

In March ~~2016,~~2020, the FASB issued ASU ~~2016-09,~~ ~~Compensation-Stock Compensation~~No. 2020-04, Reference Rate Reform (Topic ~~718): Improvements to Employee Share-Based Payment Accounting, which is intended to simplify several aspects~~848). The standard provides optional expedients for facilitating the effects of the ~~accounting~~reference rate reform on financial reporting. For the Company, there are two applicable optional expedients for ~~employee share-based payment transactions, including~~contract modifications permitted for contracts that are modified because of the ~~accounting~~reference rate reform and ~~reporting~~meet the scope guidance. The modifications of ~~income taxes,~~contracts within the ~~determination~~scope of ~~forfeiture rates,~~ASC Topic 470 should be accounted for prospectively adjusting the effective interest rate. The modifications of contracts within the scope of ASC Topic 842 should be accounted for as a continuation of the existing contracts with no reassessments of the lease classification and the discount rate or remeasurements of ~~awards~~lease payments that otherwise would be required under ASC Topic 842 for modifications not accounted for as ~~either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09~~separate contracts. The pronouncement is effective for ~~fiscal years~~all entities as of March 12, 2020 through December 31, 2022. In October 2021, the Company amended its Oxford Loan to replace its floating interest rate with the LIBOR replacement rate (see Notes 8 and ~~interim periods within those years beginning after December 15, 2016 and early adoption is permitted.~~13). The Company ~~has adopted this ASU in in the first quarter of 2017.~~ ~~As a result of adopting~~will adopt this standard when LIBOR is discontinued and does not expect the ~~Company made an accounting policy election~~adoption to ~~account for forfeitures as they occur.~~ ~~This change did not~~ have a material impact ~~to the~~on its consolidated financial statements.

Fair value accounting is applied for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). At As of September 30, ~~2017~~2021 and December 31, ~~2016,~~2020, the carrying amount of accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximated their ~~estimate~~estimated fair value due to their relatively short maturities. Management believes the terms of ~~long term~~its long-term debt reflect current market conditions for an instrument with similar terms and maturity, therefore the carrying value of the Company’s debt approximated its fair value.

Assets and liabilities recorded at fair value on a recurring basis in the unaudited condensed consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:

Level 1: Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;

Level 2: Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and

Level 3: Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.

The Company’s money market funds are classified as Level 1 because they are valued using quoted market prices. The Company’s ~~marketable~~debt securities consist of available-for-sale securities and are classified as Level 2 because their value is based on valuations using significant inputs derived from or corroborated by observable market data. There were no0 assets or liabilities classified as Level 3 as of September 30, ~~2017~~2021 and December 31, ~~2016.~~2020.

There were no0 transfers ~~between Level 1, Level 2~~into or out of Level 3 of the fair value hierarchy during the periods presented.

The following tables present the fair value hierarchy for assets and liabilities measured at fair value (in thousands):

There were no0 financial liabilities as of September 30, ~~2017~~2021 and December 31, ~~2016.~~2020.

The following ~~table summarizes~~tables summarize the estimated value of the Company’s cash equivalents and ~~marketable~~debt securities and the gross unrealized holding gains and losses (in thousands):

September 30, 2017

Amortized cost

Unrealized gain

Unrealized loss

Estimated Fair Value

Cash equivalents:

Money market fund

$
8,016

$
—

$
—

$
8,016

Commercial paper

2,000

—

—

2,000

Total cash equivalents

$
10,016

$
—

$
—

$
10,016

Marketable securities:

Corporate debt securities

$
13,033

$
—

$
(2
)

$
13,031

Commercial paper

6,233

—

—

6,233

Total marketable securities

$
19,266

$
—

$
(2
)

$
19,264

	September 30, 2021
	Amortized cost		Unrealized gain		Unrealized loss			Estimated Fair Value
Cash equivalents:
Money market funds	$	42,394	$	—	$	—		$	42,394
Total cash equivalents	$	42,394	$	—	$	—		$	42,394
Debt securities:
Corporate debt securities	$	40,799	$	—	$	(12	)	$	40,787
U.S. government bonds		30,344		13		—			30,357
Total debt securities	$	71,143	$	13	$	(12	)	$	71,144
Classified as:
Cash equivalents								$	42,394
Short-term debt securities									36,051
Long-term debt securities									35,093
								$	113,538

	December 31, 2016									December 31, 2020
	Amortized cost		Unrealized gain		Unrealized loss			Estimated Fair Value		Amortized cost		Unrealized gain		Unrealized loss			Estimated Fair Value
Cash equivalents:
Money market fund	$	9,657	$	—	$	—		$	9,657
Corporate debt securities		2,180		—		—			2,180
Money market funds										$	20,846	$	—	$	—		$	20,846
Total cash equivalents	$	11,837	$	—	$	—		$	11,837	$	20,846	$	—	$	—		$	20,846
Marketable securities:
Debt securities:
Corporate debt securities	$	9,294	$	—	$	(5	)	$	9,289	$	33,952	$	1	$	(12	)	$	33,941
Commercial paper		22,901		3		(13	)		22,891		21,980		—		—			21,980
Total marketable securities	$	32,195	$	3	$	(18	)	$	32,180
U.S. treasury bills											39,992		3		—			39,995
U.S. government bonds											4,060		—		—			4,060
Total debt securities										$	99,984	$	4	$	(12	)	$	99,976
Classified as:
Cash equivalents																		20,846
Short-term debt securities																		99,976
																	$	120,822

~~As of September 30, 2017, and December 31, 2016, the contractual maturity of the available-for-sale marketable securities is less than one year.~~ The Company periodically reviews the available-for-sale ~~investments~~securities for other-than-temporary impairment loss. The Company considers factors such as the duration, severity and the reason for the decline in value, the potential recovery period and its intent to sell. For debt securities, it also considers whether (i) it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. During the ~~three and~~ nine months ended September 30, ~~2017,~~2021, the Company did ~~not~~0t recognize any other-than-temporary impairment losses. All ~~marketable~~debt securities with unrealized losses have been in a loss position for less than ~~twelve~~ 12 months.

Prepaid expenses and other current assets consist of the following (in thousands):

On August 11, 2018, the Company entered into ~~an aggregate $25.0 million loan with Oxford Finance LLC~~a Product Development Agreement and a First Project Agreement (the ~~“Oxford Loan”).~~Product Agreements), pursuant to which the Company will receive development program support services for its HDV program. The ~~loan matures on~~services are to be provided from July 1, ~~2021. The~~2018 through the new drug application (NDA) filing. As consideration, the Company ~~borrowed $15.0~~has committed to pay fees of approximately $10.0 million in ~~December 2016 (“Tranche A”). The remaining $10.0~~cash and stock over four years, including approximately $0.8 million ~~(“Tranche B”) will be available~~for expert consultant fees and pass through costs to ~~the Company upon achievement of positive top line data from the lonafarnib Phase 2 trial in HDV, which was achieved in the fourth quarter of 2016,~~vendors, plus ~~positive top line Phase 2 data from at least one~~certain incentive-based regulatory milestone fees up to $1.0 million. As part of the ~~following programs: (i) Lambda in HDV, (ii) Exendin 9-39 in PBH based on the Company’s own IND, (iii) ubenimex in PAH, or (iv) ubenimex in Lymphedema.~~

The Oxford Loan bears interest at a floating rate per annum equal to the greater of either the 30-day U.S. Dollar LIBOR reported in the Wall Street Journal plus 6.41% or 6.95%. The Company is required to repay the Tranche A in 18 monthly interest only payments followed by 36 equal monthly payments of principal and interest commencing on the first day of the month following the funding of Tranche A. If the Company receives the Tranche B funds, then the interest only period is extended by six months followed by 30 equal monthly payments of principal plus accrued interest. At the time of finalaggregate payment, the Company ~~is required~~issued 115,526 shares of common stock subject to ~~pay an exit fee of 7.5%~~quarterly vesting requirements related to successful performance of the ~~original principal balance~~services and achievement of ~~each tranche, which will~~budget timeline set forth in the Product Agreements. The Product Agreements can be $1.1 million for Tranche A. The Company recorded as a liability and debt discount the exit fee at the origination of the term loan. In addition, the Company incurred loan origination fees and debt issuance costs of $0.3 million which were recorded as a ~~direct deduction from the carrying amount of the related debt liability. The Company is also required~~terminated by either party due to pay a 5.0% success fee within 30 days following the FDA’s approval of the Company’s first product. This fee is enforceable within 10 years from the funding of Tranche A. In connection with the execution of the Loan Agreement, the Company agreed to certain customary representations and warranties.

~~The loan is secured by the perfected first priority liens on the Company's assets, including a commitment~~material breach or by the Company to not allow any liens to be placed upon the Company’s intellectual property. The Oxford Loan includes customary events of default, including failure to pay amounts due, breaches of covenants and warranties, material adverse effect events, certain cross defaults and judgments, and insolvency. ~~If the Company is unable to comply~~without cause with these covenants or if the Company defaults on any portion of the outstanding borrowings, the lenders can also impose a 5.0% penalty and restrict access to additional borrowings under the loan and security agreement. ~~The Company was in compliance with the terms under the Oxford Loan as of September 30, 2017 and December 31, 2016.~~

The Company is permitted to make voluntary prepayments of the Oxford Loan with a prepayment fee, calculated as of the loan origination date, equal to (i) 3.0% of the loan prepaid during the first 12 months, (ii) 2.0% of the loan prepaid in months 13-24 and (iii) 1.0% of the loan prepaid thereafter. The Company is required to make mandatory prepayments of the outstanding loan upon the acceleration by lender following the occurrence of an event of default, along with a payment of the final payment, the prepayment fee and any other obligations that are due and payable at the time of prepayment.

~~The Company accounts for the amortization of the debt discount utilizing the effective interest method. The Company recorded interest expense of $0.3 million and $0.8 million for~~ 90 days prior written notice. For the three and nine months ended September 30, ~~2017. Long-term debt~~2021, the Company recognized research and ~~unamortized discount balances are~~development expense of $0.1 million and $0.2 million, respectively,related to the shares issued under the Product Agreements. Additionally, as ~~follows (in thousands):~~

of September 30, 2021, the total unrecognized compensation expense related to unvested restricted shares was $0.1 million, which the Company expects to recognize over an estimated weighted-average period of 0.5 years.

On November 20, 2020, Eiger entered into an asset purchase agreement (the APA) with AbbVie, Inc. (AbbVie) to sell its rare pediatric disease priority review voucher (the PRV), which was awarded on November 20, 2020 upon FDA approval of Zokinvy. The APA contains customary representations, warranties, covenants, and indemnification provisions subject to certain limitations.

In consideration for the PRV, AbbVie agreed to pay the Company $95.0 million. The transaction closed in January 2021. Such consideration was shared with the Progeria Research Foundation (PRF) in accordance with the terms of the PRF Collaboration and Supply Agreement, pursuant to which the Company and PRF will equally share any net proceeds from the sale of a priority review voucher that the Company may receive as the sponsor of a rare pediatric disease product application. The Company retained $46.5 million of proceeds from the sale of the PRV, net of related payments, and recorded the amount in other income, net in the unaudited condensed consolidated statement of operations for the nine months ended September 30, 2021.

In May 2017, the Company and Theragene Pharmaceuticals,Inc. ~~(“Theragene”)~~(Theragene) entered into an asset purchase agreement ~~(“Theragene APA”)~~(Theragene APA), whereby the Company sold all of the assets related to MYDICAR including any related intellectual property for a cash payment of $0.2 million and 475,000 shares of common stock of Theragene. At any time after the Theragene APA execution date and until Theragene has received cumulative gross proceeds of $4.0 million ~~(“Proceeds Date”)~~(Proceeds Date) from all equity financing transactions occurring after the Theragene APA execution date, if Theragene issues additional shares of its common stock without consideration or for a consideration per share less than $6.00 per share then Theragene will issue additional shares of its common stock to the Company concurrently with such issue, in an amount such that the per share consideration multiplied by the aggregate number of common stock shares issued to the Company will equal ~~$2.85~~$2.9 million. Additionally, the Company may exercise a put option at any time after the Proceeds Date, where upon written notice from the Company, Theragene will repurchase the 225,000 shares of its common stock held by the Company ~~(“Option Shares”)~~(Option Shares) at an aggregate purchase price equal to the greater of ~~$1.35~~$1.4 million or the aggregate fair market value of the Option Shares as of the date of the receipt of such notice. The Company is also eligible to receive contingent consideration up to a maximum $45.0 million in cash, based upon Theragene achieving certain specified future milestones. In addition, the Company is also eligible to receive up to 8% royalties on net sales of any future Theragene products covered by or involving the related patents or know-how until the 20^thtwentieth anniversary of the Theragene APA.

The Company has determined that the sale of the MYDICAR assets qualify as an asset sale and not a business.

~~As of September 30, 2017, the Company received a cash payment of $0.2 million, which was recognized as other income.~~ Concurrently with the execution of the Theragene APA, the Company became anthe owner of 475,000 shares of common stock of Theragene and held a put option for 225,000 shares of common stock of Theragene, which were recognized as a cost method investment with carrying value of ~~zero.~~0.

In September 2020, Theragene entered into an Asset Purchase Agreement with a third party for the sale of MYDICAR. Under the terms of the Theragene APA between the Company and Theragene, the Company is eligible to receive 25% of any upfront, licensee fee, milestone or other payment (other than royalty payments) received by Theragene from the sale or sublicense of MYDICAR, within 30 days of receipt of such payments by Theragene. As such, during the three and nine months ended September 30, 2021, the Company recognized 0and $0.3 million in other income, net, respectively. The Company expects to receive an additional $0.1 million subsequent to September 30, 2021.

In December 2016, the Company entered into an aggregate $25.0 million loan with Oxford Finance LLC (the Oxford Loan) with a maturity date of July 1, 2021.The Company borrowed $15.0 million in December 2016 (Tranche A). In May 2018, the Company entered into an amendment to the Oxford Loan and borrowed $5.0 million (Tranche B). On August 3, 2018, the Company borrowed the remaining $5.0 million (Tranche C) under the Oxford Loan.

On March 5, 2019, the Company entered into the third amendment to the Oxford Loan (the Amended Oxford Loan) to refinance the Oxford Loan. The Amended Oxford Loan increased the aggregate amount available to be borrowed to $35.0 million and extended the maturity date to March 1, 2024. On March 5, 2019, prior to entering into the Amended Oxford Loan, the outstanding balance of the Oxford Loan was $23.3 million. At the time of entering into the Amended Oxford Loan, the Company borrowed an additional $6.7 million in principal under the Amended Oxford Loan, which increased the total amount borrowed to $30.0 million (Amended Tranche A). The remaining $5.0 million (Amended Tranche B) was available to the Company provided that certain milestones are achieved by February 2021. The Company did not draw down the Amended Tranche B.

On February 23, 2021, the Company entered into the fifth amendment to the Oxford Loan. The amendment extended the interest only period by 17 months until September 1, 2022, followed by 19 equal monthly payments of principal and interest. Upon the receipt of the Amended Tranche B, the interest only period for borrowed funds will be extended by six months until March 1, 2023, followed by 13 equal monthly payments of principal plus accrued interest. In addition, the Company paid an amendment fee of $0.2 million to the lender on the effective date of the fifth amendment, which was recorded as an additional debt discount and is being amortized over the remaining term of the Amended Oxford Loan. The Amended Tranche B is now available to the Company provided certain milestones are achieved by August 2022.

The Amended Oxford Loan bears interest at a floating rate per annum equal to the greater of either the 30-day U.S. Dollar LIBOR reported in the Wall Street Journal plus 6.64% or 9.15%.At the time of final payment, the Company is required to pay an exit fee of 7.5% of the original principal balance of borrowed funds, or $2.3 million. In addition, the Company is required to pay an additional exit fee of $1.0 million. The Company recorded as a liability and debt discount the exit fee for the Amended Oxford Loan. At the date of the Amended Oxford Loan, the Company paid $0.9 million for the accrued portion of the Oxford Loan exit fee and the Tranche B additional exit fee. On October 6, 2021, the Company entered into the sixth amendment to the Oxford Loan to replace the floating rate with the LIBOR replacement rate upon a LIBOR transition event (see Note 13).

The Company is also required to pay a 5.0% success fee of the total amount drawn under the Amended Oxford Loan within 30 days following the FDA’s approval of the Company’s first product, excluding Zokinvy for treatment of Progeria and processing-deficient progeroid laminopathies. This fee is enforceable within 10 years from the funding of Amended Tranche A. The Company determined that the success fee met the scope exemption from derivative accounting and should be accounted for under the guidance for contingencies. Accordingly, the Company will record a liability for the success fee upon receipt of approval from the FDA. The Amended Oxford Loan includes contingent interest features and mandatory prepayment features upon an event of default that meet the definition of a derivative but were not bifurcated from the debt instrument as their fair value was deemed to be insignificant. In connection with the execution of the Oxford Loan, the Company agreed to certain customary representations and warranties.

The refinancing of the Oxford Loan did not have a material impact on terms, conditions, representations, warranties, covenants or agreements set forth in the Oxford Loan. The loan is secured by the perfected first priority liens on the Company's assets, including a commitment by the Company to not allow any liens to be placed upon the Company’s intellectual property. The loan includes customary events of default, including failure to pay amounts due, breaches of covenants and warranties, material adverse effect events, certain cross defaults and judgments, and insolvency. If the Company is unable to comply with these covenants or if the Company defaults on any portion of the outstanding borrowings, the lenders can also impose a 5.0% penalty, restrict access to additional borrowings under the loan and security agreement, and accelerate the maturity of the debt. As of September 30, 2021, the Company was in compliance with all covenants.

The Company is permitted to make voluntary prepayments of the Amended Oxford Loan with a prepayment fee, calculated as of the loan origination date, equal to (i) 2.0% of the loan prepaid during the first 12 months and (ii) 1.0% of the loan prepaid in months 13-24. The Company is required to make mandatory prepayments of the outstanding loan upon the acceleration by lender following the occurrence of an event of default, along with a payment of the final payment, the prepayment fee and any other obligations that are due and payable at the time of prepayment.

The Company accounts for the amortization of the debt discount utilizing the effective interest method. Long-term debt and unamortized discount balances are as follows (in thousands):

During the second quarter of 2021, the Company approved the 2021 Inducement Plan to reserve 850,000 shares of its common stock to be used exclusively for grants of awards to individuals that were not previously employees or directors of the Company as a material inducement to such individuals’ entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. As of September 30, 2021, there were 625,000 shares remaining available to be issued under the 2021 Inducement Plan.

The following table summarizes stock option activity under the Company’s ~~stock based~~stock-based compensation ~~plan~~plans during the nine months ended September 30, ~~2017~~2021 (in thousands, except option and share data):

Shares
Available for
Grant

Number of
Options

Weighted-
Average
Exercise
Price

Weighted-
Average
Remaining
Contractual
Life
(in Years)

Aggregate
Intrinsic
Value

Outstanding as of December 31, 2016

646,778

1,212,044

$
14.06

$
2,414

Additional options authorized

417,883

Granted

(652,200
)

652,200

$
10.91

Exercised

(5,688
)

$
2.06

Canceled and forfeited

328,162

(328,162
)

$
13.89

Outstanding as of September 30, 2017

740,623

1,530,394

$
12.80

8.31

$
2,529

Vested and exercisable as of September 30, 2017

601,330

$
14.28

7.32

$
1,286

	Shares Available for Grant			Number of Options			Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Life (in Years)		Aggregate Intrinsic Value
Outstanding as of December 31, 2020		1,021,109			3,697,075		$	10.81		7.55	$	9,048
Additional options authorized		2,543,924
Granted		(1,723,785	)		1,723,785		$	9.13
Restricted stock units granted		(371,500	)		—
Performance stock units granted		(240,000	)		—
Exercised		—			(25,945	)	$	8.07
Forfeited		16,823			(16,823	)	$	9.41
Restricted stock units forfeited		1,875			—
Outstanding as of September 30, 2021		1,248,446			5,378,092		$	10.29		7.70	$	1,489
Vested and exercisable as of September 30, 2021					2,768,024		$	11.25		6.54	$	1,016

During the three and nine months ended September 30, ~~2017,~~2021, the ~~Company granted employees stock options for 56,000 and 579,700 shares, respectively. The~~weighted-average grant date fair value of ~~these~~ options ~~was $7.45~~granted were $4.65 and ~~$7.66 for the three and nine months ended September 30, 2017,~~$6.78 per share, respectively. During the three and nine months ended September 30, ~~2016, the Company granted employees stock options for 814,028 shares~~ ~~and~~2020, the weighted-average grant date fair value of ~~these~~ options ~~was $10.58.~~ granted were $7.18 and $4.78 per share, respectively.

The Company records stock-based compensation of stock options granted ~~to employees~~ by estimating the fair value of stock-based awards using the Black-Scholes option pricing model and amortizes the fair value of the stock-based awards granted over the applicable vesting period of the awards on a straight-line basis. The fair value of ~~employee~~ stock options was estimated using the following weighted-average assumptions:

In the first quarter of 2020, the Company revised its non-employee director compensation policy to ~~Non-Employees~~approve the granting of restricted stock units (RSUs) in accordance with the Restated 2013 Equity Incentive Plan (the Restated 2013 Plan). Each eligible director who has served for at least six months during the prior calendar year and continues to serve as a non-employee member of the board is granted RSUs. Each eligible director who has served on the Board for less than six months during the prior calendar year and who continues to serve as a non-employee member of the Board, is granted RSUs which are pro-rated for the period served during the prior calendar year.

The RSUs granted to non-employee directors will vest on the one-year anniversary of the grant date, subject to the eligible director’s continuous services through the vesting date, and will vest in full upon a change in control, as defined under the Restated 2013 Plan. The RSUs granted to employees will begin vesting on the one-year anniversary through the two-year anniversary of the grant date. The fair value of all RSUs is measured at the grant date based on the closing market price of the Company’s common stock and is recognized as stock-based compensation expense on a straight-line basis over the vesting period.

In the third quarter of 2021, the Company ~~grants~~granted performance stock ~~options~~units (PSUs) pursuant to ~~non-employees~~the Restated 2013 Plan. Each PSU, which is a stock award, is earned through the achievement of a performance-based metric over a defined performance period. The length of the defined performance period, the performance-based metric to be achieved during the defined performance period, and the measure of whether and to what degree such performance-based metric has been achieved will be conclusively determined by the compensation committee of the Company’s board of directors, in ~~exchange for services rendered.~~its sole discretion. The estimated fair value of equity awards that contain performance conditions is expensed over the term of the award once the Company has determined that it is probable that

performance conditions will be satisfied. During the three and nine months ended September 30, ~~2017,~~2021, the Company granted ~~to non-employees stock options for 20,000 and 72,500 shares, respectively.~~ 240,000 PSUs with a weighted-average grant date fair value of $8.15 per share. As of September 30, 2021, no PSUs have vested as the performance-based metrics of the PSUs have not yet been achieved.

During the three ~~and~~months ended September 30, 2021, the Company granted 168,000 RSUs with a weighted-average grant date fair value of $8.15 per share. There were 0 RSUs granted during the three months ended September 30, 2020. During the nine months ended September 30, ~~2016,~~2021 and 2020, the Company granted 371,500 and 37,500 RSUs, respectively, with a weighted-average grant date fair value of $9.16 and $6.95 per share, respectively.

In relation to ~~non-employees stock options~~the RSUs granted, the Company recognized $0.4 million and $0.1 million in stock-based compensation expense for ~~zero~~the three months ended September 30, 2021 and ~~48,544 shares, respectively. Stock-based~~2020, respectively, and $0.7 million and $0.1 million in stock-based compensation expense for the nine months ended September 30, 2021 and 2020, respectively, which were included in selling, general and administrative expenses. As of September 30, 2021, the total unrecognized compensation expense related to ~~stock options granted~~unvested RSUs and PSUs was $4.7 million, which the Company expects to ~~non-employees is recognized as the stock options are earned~~recognize over an estimated weighted-average period of 3.0 years.

The following table summarizes RSU and ~~will fluctuate as the estimated~~PSU activity and weighted average grant date fair value offor the ~~common stock fluctuates until the awards vest. The Company believes that the estimated fair value of the stock options is more readily measurable than the fair value of the services rendered.~~

~~The fair value of the stock options granted~~ ~~to non-employees~~ ~~is estimated at each reporting date using the Black-Scholes option-pricing model~~ ~~using similar assumptions as for employees except that the expected term is based on the options’ remaining contractual term instead of the simplified method:~~nine months ended September 30, 2021:

Total stock-based compensation expense recognized ~~for options granted to employees and non-employees~~ was as follows (in thousands):

As of September 30, ~~2017,~~2021, the total unrecognized compensation expense related to unvested ~~employee~~ options was ~~$7.5~~$16.8 million, which the Company expects to recognize over an estimated weighted average period of ~~2.9~~2.8 years.

The Company’s provision for income taxes was approximately $16,000 and $46,000 for the three and nine months ended September 30, 2021, respectively, with an effective tax rate of 0.3% for the nine months ended September 30, 2021. The Company did 0t record tax expense for the three and nine months ended September 30, ~~2017 was zero~~2020 due to the Company’s loss position and full valuation allowance. ~~This~~The effective tax rate in each period differs from the U.S. statutory tax rate primarily due to the valuation allowances on the Company’s deferred tax assets as it is ~~consistent with~~more likely than not that some or all of the ~~zero-tax~~Company’s deferred tax assets will not be realized. The tax expense recorded for the three and nine months ended September 30, ~~2016.~~2021 relates to state taxes.

In July 2015, following Celladon’s announcements of the negative CUPID 2 data and the suspension of further research and development activities and the subsequent declines of the price of its common stock, three putative class actions were filed in the U.S. District Court for the Southern District of California against Celladon and certain of its current and former officers. The complaints generally alleged that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), by making materially false and misleading statements regarding the clinical trial program for MYDICAR, thereby artificially inflating the price of Celladon’s common stock. The complaints sought unspecified monetary damages and other relief, including attorneys’ fees. On December 9, 2015, the district court consolidated the three putative securities class actions and appointed a lead plaintiff to represent the putative class. The lead plaintiff filed a consolidated amended complaint on February 29, 2016.

On October 7, 2016, the district court granted defendants’ motion to dismiss the consolidated amended complaint and granted leave to amend within 60 days from the date of the district court’s order. The lead plaintiff subsequently filed a notice of intent not to amend the consolidated amended complaint and instead indicated that it intended to appeal the district court’s decision. On December 9, 2016, the district court closed the case.

On December 28, 2016, the lead plaintiff filed a notice to the United States Court of Appeals for the Ninth Circuit appealing the district court’s order dismissing the consolidated amended complaint. On May 5, 2017, the lead plaintiff and appellant filed his opening appellate brief. On July 5, 2017, defendants filed their answering appellate brief.

It is possible that additional suits will be filed, or allegations made by stockholders, with respect to these same or other matters and also naming the Company and/or Celladon’s former officers and directors as defendants. The Company believes that it has meritorious defenses and intends to defend these lawsuits vigorously. Due to the early stage of these proceedings, the Company is not able to predict or reasonably estimate the ultimate outcome or possible losses relating to these claims.

In ~~March~~October 2017, the Company entered into a non-cancelable operating facility lease agreement for an8,029 square feet of office ~~facility~~space located at 2155 Park Blvd. in Palo Alto, California. The lease commenced on ~~April~~March 1, ~~2017~~2018 and expires ~~12 months after the commencement date.~~in February 2023. The lease has ~~one twelve-month~~a three-year renewal option prior to ~~expiration and~~expiration; however, the Company is not reasonably assured to exercise this option. The lease includes rent escalation clauses ~~through~~throughout the lease term. In ~~April~~October 2017, the Company provided a security deposit of ~~$27,000~~$0.3 million. The Company also has additional operating leases that are included in its lease accounting but are not considered significant for disclosure.

The maturity of the Company’s operating lease liabilities as ~~collateral~~of September 30, 2021 were as follows (in thousands):

Rent expense recognized for the ~~lease. The~~ ~~future minimum rent payable under~~Company’s operating leases was $0.1 million and $0.2 million for the ~~new~~three months ended September 30, 2021 and 2020, respectively, and $0.4 million and $0.5 million for the nine months ended September 30, 2021 and 2020, respectively. Under the terms of the lease ~~agreement~~agreements, the Company is ~~approximately $0.3~~also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments for the operating leases were $23,000 for the three months ended September 30, 2021 and 2020 and $0.1 million for the nine months ended September 30, 2021 and 2020.

The operating cash outflows for the operating lease liabilities were $0.5 million and $0.5 million for the nine months ended September 30, 2021 and 2020, respectively. As of September 30, 2021 and December 31, 2020, the weighted-average remaining lease terms were 1.4 years and 2.1 years, and weighted-average discount rates were 9.15% and 9.15%, respectively.

Basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the ~~next year.~~

~~There were no other changes~~period, without consideration for potentially dilutive securities. Since the Company was in ~~commitments~~a loss position for the three months ended September 30, 2021 and ~~contingencies during the three~~2020, and nine months ended September 30, ~~2017.~~2021 and 2020, diluted net loss per share is the same as basic net loss per share as the inclusion of all potential common shares outstanding would have been anti-dilutive. Dilutive potential common stock equivalents include the assumed exercise, vesting and issuance of employee stock awards using the treasury stock method.

On October ~~27, 2017,~~6, 2021, the Company entered into ~~an underwriting agreement (the “Underwriting Agreement”) with BTIG, LLC (the “Underwriter”) relating~~the sixth amendment to the ~~offering, issuance and sale (the “Offering”)~~Oxford Loan. Prior to the sixth amendment, the Amended Oxford Loan currently bears interest at a floating rate per annum equal to the greater of ~~1,854,749 shares~~either the 30-day U.S. Dollar LIBOR reported in the Wall Street Journal plus 6.64% or 9.15%. The latest amendment replaces this rate with the LIBOR replacement rate upon a LIBOR transition event. As a result, the Amended Oxford Loan will bear interest at the LIBOR replacement rate which is the sum of the ~~Company’s common stock, par value $0.001 per share. The price in~~alternate benchmark rate and the ~~Offering was $10.00 per share. The Underwriter had a 30-day option to purchase up to an additional 278,212 shares~~LIBOR replacement spread. An estimate of ~~common stock, which was exercised on October 27, 2017. On October 31, 2017, pursuant~~the impact of the change to the ~~Underwriting Agreement,~~LIBOR replacement rate on the ~~Underwriters purchased shares of common stock from~~financial statements cannot be made until the Company at a price of $9.40 per share, which resulted in approximately $19.5 million of net proceeds to the Company after deducting the underwriting discount and offering expenses payable by the Company. The shares of common stock are listed on The NASDAQ Global Market. Alloccurrence of the ~~shares in~~LIBOR transition event. The Company does not expect the ~~Offering were sold by the Company. Pursuant~~impact of this change to the terms of the Underwriting Agreement, each of the Company’s directors and officers have entered into “lock-up” agreements with Underwriter that generally prohibit, without prior written consent of BTIG, LLC, the sale, transfer or other disposition of securities of the Company for a period ending 75 days after October 27, 2017. The Offering was made pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-212114) filed with the Securities and Exchange Commission (the “SEC”) on June 17, 2016 and declared effective on August 4, 2016.

You should read the following discussion and analysis of Eiger’s financial condition and results of operations together with our unaudited condensed consolidated financial statements and related notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q, ~~Eiger’s~~and our consolidated financial statements and related notes thereto for the year ended December 31, ~~2016,~~2020, included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March ~~23, 2017.~~9, 2021. This discussion and other parts of this report contain forward-looking statements that involve risks and uncertainties, such as our plans, objectives, expectations, intentions and beliefs. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section entitled “Risk Factors” included elsewhere in this report.

This Quarterly Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements In some cases, forward-looking statements are identified by words such as “believe,” “will,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “could,” “potentially” or the negative of these terms or similar expressions. You should read these statements carefully because they discuss future expectations, contain projections of future results of operations or financial condition, or state other “forward-looking” information. These statements relate to, among other ~~thing,~~things, our future plans, objectives, expectations, intentions, the potential for our programs, the timing of our clinical trials and financial performance and the assumptions that underlie these statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in this Quarterly Report on Form 10-Q in Part II, Item 1A — “Risk Factors,” and elsewhere in this Quarterly Report on Form 10-Q. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. These statements, like all statements in this Quarterly Report on Form 10-Q, speak only as of their date, and we undertake no obligation to update or revise these statements in light of future developments. We caution investors that our business and financial performance are subject to substantial risks and uncertainties.

We are a ~~clinical stage~~commercial-stage biopharmaceutical company focused on ~~bringing to market novel product candidates~~the development and commercialization of well-characterized drugs for serious rare and ultra-rare diseases with high unmet medical needs. Our lead clinical programs focus on the ~~treatment~~development of ~~orphan diseases. Since~~complementary, foundational therapies for Hepatitis Delta Virus (HDV), the most severe form of viral hepatitis, for which there is currently no FDA-approved therapy. We have reported positive proof-of-concept clinical results across all our ~~founding in 2008, we~~programs. All five of our rare disease programs have ~~worked with investigators at Stanford University and evaluated a number of potential development candidates from pharmaceutical companies to comprise a pipeline of novel product candidates.~~ FDA Breakthrough Therapy Designation.

Our ~~resulting pipeline includes four Phase 2 candidates addressing four distinct orphan diseases. The~~ programs have several aspects in common: the disease targets represent conditions of high unmet medical ~~need which are inadequately treated by current standard of care;~~need; the therapeutic approaches are supported by an understanding of disease biology and mechanism as elucidated by our academic research relationships; prior clinical experience with the product candidates guides an understanding of safety; and the development paths leverage the experience and capabilities of our experienced, commercially-focused management team.

We are developing two complementary treatments for HDV. Lonafarnib is a first-in-class oral farnesylation inhibitor and peginterferon lambda is a first-in-class, type III, well-tolerated interferon. Both lonafarnib and peginterferon lambda are in global Phase 3 trials.

The ~~pipeline includes~~pivotal Phase 3 D-LIVR study (N=400) of lonafarnib boosted with ritonavir in HDV is ongoing and has recently completed enrollment of over 400 patients. The study spans approximately 20 countries and over 100 sites and has potential to generate data for ~~Hepatitis Delta Virus,~~two lonafarnib-based ritonavir-boosted regimens for approval. An all-oral arm of lonafarnib boosted with ritonavir and a combination arm of lonafarnib boosted with ritonavir combined with pegylated interferon-alfa-2a will each be compared to placebo.

Peginterferon lambda is our second program in development for HDV and is entering Phase 3. We have concurrence with the FDA and EMA on a single pivotal Phase 3 study called LIMT-2 (N=150). Peginterferon lambda is a first-in-class, type III, well-tolerated interferon. We previously reported Phase 2 LIMT-1 (peginterferon lambda monotherapy) study results (N=33) where we observed, after 48 weeks of treatment, a durable virologic response (DVR) or ~~HDV,~~below the limit of quantification (BLQ) at 24 weeks post-treatment in 36% of patients.

We have also generated data from the combination of lonafarnib and peginterferon lambda for treatment of HDV. In the Phase 2 LIFT study, 26 HDV ~~exendin 9-39~~patients were treated for ~~Post-Bariatric Hypoglycemia,~~24 weeks with a combination of our two proprietary products, peginterferon lambda and lonafarnib boosted by ritonavir. The end-of-study results based on a per-protocol analysis reported in November 2020 showed that 77% of patients achieved the primary endpoint of ≥ 2 log decline in HDV RNA at Week 24 and 50% of patients were HDV RNA BLQ or undetectable. At end of 24 weeks follow-up, 23% of patients maintained HDV RNA BLQ or undetectable; 55% of patients demonstrated improvement in histology. Adverse events were mostly mild to moderate.

We are also developing avexitide, a first in class, a well-characterized GLP-1 antagonist, as a targeted treatment for two metabolic diseases with high unmet medical needs and no approved therapies: post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI). We have completed four clinical studies demonstrating proof of concept in 54 patients suffering from severe, refractory PBH, and ~~ubenimex~~have agreement with FDA and EMA on a single pivotal Phase 3 trial (N=90). Avexitide has been granted FDA Breakthrough Therapy Designation for ~~Pulmonary Arterial Hypertension, or PAH, and lymphedema. We plan to deliver data from all ongoing~~PBH. Avexitide has also demonstrated proof of concept in Phase 2 ~~clinical trials over~~for treatment of HI, an ultra-rare pediatric metabolic genetic disorder which has been granted FDA Rare Pediatric Disease Designation and FDA Breakthrough Therapy Designation.

The FDA approved our first commercial product, Zokinvyâ (lonafarnib) to reduce risk of mortality of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and for treatment of processing-deficient progeroid laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation, or homozygous or compound heterozygous ZMPSTE24 mutations, ultra-rare and rapidly fatal genetic conditions of accelerated aging in children, on November 20, 2020. Our Marketing Authorization Application (MAA) is under review with the ~~course~~EMA, and we expect an opinion from the CHMP around the end of ~~the next fifteen months.~~2021.

We ~~have no products approved for commercial sale~~commercially launched Zokinvy in the U.S. in January 2021 and ~~have not generated any~~started to record product revenue ~~from product sales.~~in first quarter 2021. We have ~~never been profitable and have~~historically incurred operating losses in each year since inception and were profitable during the nine months ended September 30, 2021 due to the one-time gain from the sale of a priority review voucher issued upon the FDA approval of Zokinvy. However, we ~~do not anticipate that we will achieve profitability in~~expect to incur losses for the ~~near term. Our~~foreseeable future. We had net ~~losses were $31.6~~loss of $22.2 million and ~~$34.3~~$15.7 million for the three months ended September 30, 2021 and 2020, respectively. We had net loss of $12.1 million for the nine months ended September 30, ~~2017~~2021 and ~~2016, respectively.~~net loss of $46.2 million for the nine months ended September 30, 2020. As of September 30, ~~2017,~~2021, we had an accumulated deficit of ~~$107.9~~$318.6 million. Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from selling, general and administrative costs associated with our operations.

We expect to incur significant expenses and increasing operating losses for at least the next several years as we initiate and continue the clinical development of, and seek regulatory approval for, and potentially commercialize our product candidates and add personnel necessary to operate as a public company with an advanced clinical candidate pipeline of products. In addition, we ~~are now operating~~will incur costs for additional personnel and upgrades to our information technology systems as ~~a publicly traded company following the merger with Celladon in 2016, and~~ we ~~have and will be hiring additional financial and other personnel, upgrading our financial information systems and incurring costs associated with operating as a public~~transition from an emerging growth company. We expect that our operating losses will fluctuate significantly from quarter to quarter and year to year due to timing of clinical development programs and efforts to achieve additional regulatory ~~approval.~~approvals.

Completion of Enrollment of D-LIVR, the Largest Phase 3 Study in Hepatitis Delta Virus (HDV), Investigating Lonafarnib, the Only Oral Agent in Development for HDV

In November 2021, we announced completion of enrollment in the Phase 3 D-LIVR study evaluating two different treatment regimens containing Lonafarnib, our first-in-class oral prenylation inhibitor, for the treatment of chronic Hepatitis Delta Virus (HDV) infection. The two regimens include all-oral Lonafarnib boosted with ritonavir and in combination with peginterferon alfa. The D-LIVR study spans over 100 clinical sites across over 20 countries and is the largest Phase 3 study ever conducted in chronic HDV infection. Over 400 patients have now been enrolled in D-LIVR. Eiger is planning for topline data release by the end of 2022.

Approval of Cohort Temporary Use Authorization Program (ATU) in France for Zokinvy^® for Progeria in France

In November 2021, we announced that the French National Agency for Medicines and Health Products Safety (Agence nationale de sécurité du médicament et des produits de santé, or ANSM) authorized a cohort ATU for Zokinvy for Progeria. In France, ATUs are reserved for products whose efficacy and safety are “strongly presumed” based on clinical trial data and whose therapeutic indication targets a serious, rare or disabling disease lacking appropriate treatment.

~~On March 22, 2016,~~Positive Interim Analysis and Continuation of Dosing of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients

In September 2021, we ~~completed~~announced that an independent Data Safety Monitoring Board (DSMB) recommended that investigators continue enrollment of the ~~merger between Private~~peginterferon lambda arm in the Phase 3 TOGETHER investigator-sponsored platform study. The per protocol interim futility analysis was based on a sample size of 453 patients, randomized 1:1 active treatment to placebo. Peginterferon Lambda is currently the only remaining investigational agent in TOGETHER.

In September 2021, we announced the appointment of Erik Atkisson as Eiger’s General Counsel and Chief Compliance Officer. Mr. Atkisson brings over twenty years of experience to Eiger, and ~~Celladon in accordance with the terms~~was most recently Chief Compliance Officer, Legal Counsel, and Privacy Officer at Cytokinetics, Incorporated, where he was responsible for legal matters related to corporate securities, licensing, partnerships and collaborations, and compliance. Mr. Atkisson earned a B.A. from Harvard University, an M.Sc. from University of ~~the Agreement~~Edinburgh, and Plan of Merger, dated as of November 18, 2015, by and among Private Eiger, Celladon and Celladon Merger Sub, Inc., or the Merger. Also on March 22, 2016, in connection with, and prior to the completion of the Merger, we effected a fifteen for one reverse stock split of our common stock, or the Reverse Stock Split, and changed our name to “Eiger BioPharmaceuticals, Inc.”J.D. from Georgetown University Law Center.

On November 18, 2015, in connection with the Merger, we entered into a subscription agreement, or the “Subscription Agreement” with investors for the sale of shares of our common stock, or the “Private Placement”, which closed on March 22, 2016.

Immediately prior to and in connection with the Merger, each share of Private Eiger’s preferred stock outstanding was converted into shares of Private Eiger’s common stock at an exchange ratio of one share of common stock for each share of preferred stock.

Under the terms of the Merger Agreement, at the effective time of the Merger, Celladon issued shares of common stock to Private Eiger stockholders, at an exchange ratio of approximately 0.09 shares of common stock, after taking into account the Reverse Stock Split, in exchange for each share of Private Eiger’s common stock outstanding immediately prior to the Merger. The exchange ratio was calculated by a formula that was determined through arms-length negotiations between Celladon and Private Eiger. Immediately after the Merger, the former Private Eiger equity holders beneficially owned approximately 78% of post-merger Eiger’s common stock. The Merger was accounted for as a reverse asset acquisition.

Ourproduct revenue, net consists of sales of Zokinvy in the United States. Prior to 2021, we did not have any product revenue.

Cost of sales consists primarily of direct and indirect costs related to the manufacturing of Zokinvy for commercial sale, including third-party manufacturing costs, third party logistics costs, write down of inventories, and other period costs. Costs incurred prior to FDA approval in November 2020 have been recorded as research and development expense.

Research and development expenses represent costs incurred to conduct research and development, such as the development of our product candidates. We recognize all research and development costs as they are incurred. Research and development expenses consist primarily of the following:

The largest component of our operating expenses has historically been the investment in clinical trials, including contract manufacturing ~~capabilities,~~arrangements, clinical trial material related costs and other research and development activities. However, we do not allocate internal research and development costs, such as salaries, benefits, stock-based compensation expense and indirect costs to product candidates on a program-specific basis. The following table shows our research and development expenses for the three and nine months ended September 30, ~~2017~~2021 and ~~2016~~2020 (in thousands):

Three Months Ended September 30,

Nine Months Ended September 30,

2017

2016

2017

2016

Product candidates:

Lonafarnib HDV

$
715

$
1,020

$
3,105

$
3,771

Lambda HDV

719

648

2,141

6,103

Exendin 9-39 PBH

721

1,104

2,540

1,919

Ubenimex PAH

1,994

3,189

7,633

7,299

Ubenimex Lymphedema

500

1,164

1,359

1,787

Internal research and development costs

1,496

947

4,962

2,758

Total research and development expense

$
6,145

$
8,072

$
21,740

$
23,637

	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Product candidates:
Lonafarnib	$	9,276	$	6,082	$	24,609	$	18,997
Peginterferon Lambda		5,379		1,061		12,292		2,238
Avexitide		507		431		1,303		1,632
Internal research and development costs		2,944		2,236		8,046		6,178
Total research and development expense	$	18,106	$	9,810	$	46,250	$	29,045

We expect research and development expenses will continue to be significant and may increase in the future as we advance our product candidates into and through later stage clinical trials and pursue regulatory approvals, which will require a significant investment in regulatory support and contract manufacturing and clinical trial material related costs. In addition, we continue to evaluate opportunities to acquire or in-license other product candidates and technologies, which may result in higher research and development expenses due to license ~~fee~~fees and/or milestone payments.

The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We may never succeed in timely developing and achieving regulatory approval for our product candidates. The probability of success of our product candidates may be affected by numerous factors, including clinical data, competition, intellectual property rights, manufacturing capability and commercial viability. As a result, we are unable to determine the duration and completion costs of our development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates. The COVID-19 pandemic presents additional risks and uncertainties associated with developing drugs, including:

~~General~~Selling, general and administrative expenses consist of personnel costs, allocated expenses and expenses for outside professional services, including legal, audit, accounting services, insurance costs and costs associated with being a public company. Personnel costs consist of salaries, benefits and stock-based compensation. Allocated expenses consist of facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation expense and other supplies. ~~During the nine months ended September 30, 2016, we incurred incremental expenses as a result of the Merger. As a result of becoming a public company following completion of the Merger,~~Our expenses include costs related to compliance with the rules and regulations of the SEC and ~~NASDAQ, additional~~Nasdaq, insurance, investor relations, banking fees and other administrative expenses and professional services. We expect our selling, general and administrative expenses to increase in the future due to sales and marketing activities from the commercialization of our product candidates.

Interest expense ~~for the three and nine months ended September 30, 2017,~~ consists of interest and amortization of the debt discount related to the Oxford Loan borrowing in December 2016. Interest expense for the nine months ended September 30, 2016, consists of interest and amortization of the debt discount related to the outstanding convertible promissory notes issued in November 2015 and then converted into common stock in March 2016, or “the Notes”.Loan.

Interest income consists of ~~interests~~interest earned on our investments in ~~marketable~~debt securities and cash equivalents.

Other income, net ~~for the three and nine months ended September 30, 2017,~~ primarily consists of the ~~payment received for MYDICAR sale.~~

~~Other expense, net for~~gain we recognized in connection with the ~~nine months ended September 30, 2016, consists of the change in fair value of the obligation to issue common stock to Eiccose and the change in fair value of warrant liability.~~

The change in fair value of the obligation to issue common stock to Eiccose was related to our obligation to issue shares to Eiccose upon the closing of the next round of financing that resulted in at least $25.0 million in gross proceeds to us. Upon the closing of the Private Placement on March 22, 2016, we issued to Eiccose 96,300 fully vested sharessale of our ~~common stock in settlement of this obligation. In connection with this transaction we remeasured the fair value of the obligation~~rare pediatric disease priority review voucher to issue common stock at the settlement date and the change in fair value of $0.2 million was recognized within other expense, net during the nine months ended September 30, 2016. Upon the settlement of the obligation with the issuance of shares on March 22, 2016, the liability was reclassified to common stock and additional paid-in capital within stockholders’ equity.

In connection with our issuance of the Notes, we issued warrants to the noteholders to purchase shares of our common stock at an exercise price of $0.11 per share, on a post-Merger and post-Reverse Stock Split basis, or the Warrants. The number of shares into which the Warrants could be exercised was equal to the warrant coverage amount divided by the per share price of the equity securities sold in a qualified financing and thus was accounted for as a liability. Upon the closing of the Private Placement on March 22, 2016, the number of shares of common stock issuable upon exercise of the Warrants was fixed and the fair value remeasured at that date, and the warrants were automatically exercised. During the nine months ended September 30, 2016, we recognized a loss related to the change in fair value of the warrant liability of $0.2 million. The warrant liability was reclassified to common stock and additional paid-in capital within stockholders’ equity, upon the exercise of the Warrants and issuance of shares on March 22, 2016.AbbVie Inc.

Our management’s discussion and analysis of financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis, we evaluate these estimates and judgments. We base our estimates on historical experience and on various assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenues and expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates.

~~There have been no material changes~~ We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management’s judgments and estimates. Our critical accounting policies ~~during the nine months ended September 30, 2017 as compared to the critical accounting policies~~are consistent with those disclosed in our 2020 Annual Report on Form 10-K filed with SEC on March 9, 2021 other than as disclosed below.

Prior to regulatory approval of our product candidates, expenses incurred to manufacture drug products are recorded as research and development expense. We begin capitalizing these expenses as inventory upon regulatory approval. We periodically assess the recoverability of our inventory and reduce the carrying value of the inventory when items are determined to be obsolete, defective or in excess of forecasted sales requirements. Inventory write-downs for excess, defective and obsolete inventory are recorded as a cost of sales. There have been no write-downs of inventories for the ~~year ended December 31, 2016.~~periods presented.

We recognize revenue upon transfer of control of promised products to customers in an amount that reflects the consideration we expect to receive in exchange for those products.To determine revenue recognition for contracts with customers, we perform the following five-step approach: (i) identify the contract, or contracts, with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the performance obligation is satisfied. The five-step model is only applied to contracts when it is probable that we will collect substantially all of the consideration we are entitled to in exchange for the goods transferred to the customer.

We received FDA approval for our first product, Zokinvy, to reduce the risk of mortality in Progeria, and for treatment of processing-deficient progeroid laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation, or homozygous or compound heterozygous ZMPSTE24 mutations, ultra-rare and rapidly fatal genetic conditions of accelerated aging in children, in November 2020 which we launched in the United States in January 2021. We currently have one customer, a specialty pharmacy provider, that subsequently dispenses the product directly to patients. We recognize product revenue when the customer obtains control of its product, which occurs at a point in time, typically upon delivery to the customer as the delivery of the product is our only performance obligation.

Rebates: Our products are subject to government mandated rebates for Medicaid Drug Rebate Program, Medicare Part D Prescription Drug Benefit Program, and other government health care programs in the United States. Rebate amounts are based upon contractual agreements or legal requirements with public sector benefit providers. We use the expected-value method for estimating these rebates based on statutory discount rates and expected utilization. The expected utilization of rebates is estimated based on expected coverage of identified patients. Estimates for these rebates are adjusted quarterly to reflect the most recent information. We record an accrued liability for unpaid rebates related to products for which control has been transferred to the customer.

Prompt payment discounts: We provide a discount to our customer if they pay for purchases within 30 days. We expect that our customer will earn prompt payment discounts and we use the most likely amount method for estimating such discounts. As a result, when revenues are recognized, we deduct the full amount of the prompt payment discounts from total product revenues and record these discounts as a reduction of accounts receivable.

Co-payment assistance: We provide co-payment assistance to patients who have commercial insurance and meet certain eligibility requirements. We use the expected-value method for estimating co-payment assistance based on estimates of program redemption using data provided by third-party administrators. Estimates for the co-payment assistance are adjusted quarterly to reflect actual experience. We record an accrued liability for unredeemed co-payment assistance related to products for which control has been transferred to the customer.

Product returns: We offer limited product return rights and generally allow for the return of product that is damaged or defective, or within a few months prior to and up to a few months after the product expiration date. We consider several factors in the estimation of potential product returns, including expiration dates of the product shipped, the limited product return rights, third-party data in monitoring channel inventory levels, shelf life of the product, and other relevant factors.

Comparison of the Three Months Ended September 30, ~~2017~~2021 and ~~2016~~2020

The following table summarizes results of operations for the three months ended September 30, 2021 and 2020 (in thousands):

	Three Months Ended September 30,						$			%			Three Months Ended September 30,						$			%
	2017			2016			Change			Change			2021			2020			Change			Change
Operating expenses:
Product revenue, net													$	3,039		$	—		$	3,039		*
Costs and operating expenses:
Cost of sales														318			—			318		*
Research and development	$	6,145		$	8,072		$	(1,927	)		24	%		18,106			9,810			8,296			85	%
General and administrative		2,727			3,264			(537	)		16	%
Total operating expenses		8,872			11,336			(2,464	)
Selling, general and administrative														6,466			5,027			1,439			29	%
Total costs and operating expenses														24,890			14,837			10,053			68	%
Loss from operations		(8,872	)		(11,336	)		2,464						(21,851	)		(14,837	)		(7,014	)		47	%
Interest expense		(388	)		—			(388	)		100	%		(894	)		(906	)		12		*
Interest income		98			—			98			100	%		35			76			(41	)		(54	)%
Other income (expense), net		(8	)		(34	)		26		*%				503			(13	)		516		*
Loss before provision for income taxes														(22,207	)		(15,680	)		(6,527	)		42	%
Provision for income taxes														16			—			16		*
Net loss	$	(9,170	)	$	(11,370	)	$	2,200			19	%	$	(22,223	)	$	(15,680	)	$	(6,543	)		42	%

Research and development expenses ~~decreased~~increased by ~~$2.0~~$8.3 million to ~~$6.1~~$18.1 million for the three months ended September 30, ~~2017,~~2021, from ~~$8.1~~$9.8 million for the same period in ~~2016.~~2020. The ~~decrease~~increase was primarily due to a ~~$2.6~~$8.2 million ~~decrease~~increase incontract manufacturing and clinical ~~and drug supply~~ expenditures due to ~~decreased~~an increase in clinical program ~~activity. The decrease~~activities and a $0.8 million increase in headcount related expenses, including stock-based compensation expense. It was partially offset by a ~~$0.3~~$0.7 million ~~increase~~decrease in ~~compensation~~outside services, including consulting and personnel related expenses due to an increase in headcount and severance payments, $0.2 million in milestone payments to two Stanford University inventors, and a $0.1 million increase in facility and insurance expenses related to increase in operating activity.advisory services.

~~General~~Selling, general and administrative expenses ~~decreased~~increased by ~~$0.6~~$1.5 million to ~~$2.7~~$6.5 million for the three months ended September 30, ~~2017~~2021, from ~~$3.3~~$5.0 million for the same period in ~~2016.~~2020. The ~~decrease~~increase was primarily due to a ~~$0.4~~$0.8 million ~~decrease~~increase in ~~stock-based compensation expense due to changes in headcount and a higher level of stock-based compensation expense in the comparative third quarter 2016, and a $0.2 million decrease in legal,~~outside services, including consulting, advisory and accounting services, and a $0.8 million increase in headcount related expenses, including stock-based compensation expense. It was partially offset by a $0.1 million decrease in sales and marketing expenses.

Other income, net increased by $0.5 million compared to the same period in 2020. The increase was primarily due to proceeds from a corporate insurance settlement.

Provision for income taxes increased by $16,000 compared to the same period in 2020. The increase was primarily due to the ~~incremental expenses incurred as a result of the Merger in the first quarter 2016.~~

~~Interest expense increased by $0.4 million for the three months ended September 30, 2017, and consisted of interest and amortization of the debt discount~~ related to ~~the Oxford Loan borrowings in December 2016. There was no interest expense for the three months ended September 30, 2016.~~

Interest income decreased by $0.1 million for the three months ended September 30, 2017, due to the interest earned on our investments in marketable securities and cash equivalents. There was no interest income earned for the three months ended September 30, 2016, as funds were not invested until the fourth quarter in 2016.

The following table summarizes results of operations for the nine months ended September 30, 2021 and 2020 (in thousands):

	Nine Months Ended September 30,						$			%			Nine Months Ended September 30,						$			%
	2017			2016			Change			Change			2021			2020			Change			Change
Operating expenses:
Product revenue, net													$	8,782		$	—		$	8,782		*
Costs and operating expenses:
Cost of sales														641			—			641		*
Research and development	$	21,740		$	23,637		$	(1,897	)		8	%		46,250			29,045			17,205			59	%
General and administrative		9,195			9,574			(379	)		4	%
Total operating expenses		30,935			33,211			(2,276	)
Selling, general and administrative														17,916			15,141			2,775			18	%
Total costs and operating expenses														64,807			44,186			20,621			47	%
Loss from operations		(30,935	)		(33,211	)		2,276						(56,025	)		(44,186	)		(11,839	)		27	%
Interest expense		(1,129	)		(685	)		(444	)		65	%		(2,659	)		(2,681	)		22		*
Interest income		321			—			321			100	%		119			629			(510	)		(81	)%
Other income (expense), net		188			(423	)		611			144	%		46,462			(7	)		46,469		*
Loss before provision for income taxes														(12,103	)		(46,245	)		34,142			(74	)%
Provision for income taxes														46			—			46		*
Net loss	$	(31,555	)	$	(34,319	)	$	2,764			8	%	$	(12,149	)	$	(46,245	)	$	34,096			(74	%)

Product revenue, net consists of sales of Zokinvy, which was approved by the FDA in November 2020 and launched commercially in January 2021.

Cost of sales of $0.6 million for the nine months ended September 30, 2021, is related to certain costs associated with Zokinvy incurred after FDA approval. Prior to receiving FDA approval for Zokinvy in November 2020, we recorded all manufacturing costs incurred as research and development expense. We expect to sell inventory previously expensed to research and development over approximately the current year, and accordingly we expect our costs of product sales of Zokinvy to increase as a percentage of net sales in future periods as we produce and sell inventory that reflects the full cost of manufacturing the product.

Research and development expenses ~~decreased~~increased by ~~$1.9~~$17.2 million to ~~$21.7~~$46.2 million for the nine months ended September 30, ~~2017~~2021, from ~~$23.6~~$29.0 million for the same period in ~~2016.~~2020. The ~~decrease~~increase was primarily due to a ~~$5.2 million upfront payment under our License Agreement with Bristol Myers Squibb Company~~ ~~that was recognized in the second quarter 2016. There were no similar payments during the same period in 2017. The decrease was offset by a $1.6~~an $16.6 million increase in ~~compensation~~contract manufacturing and ~~personnel related expenses~~clinical expenditures due to an increase in ~~headcount,~~clinical program activities and a ~~$0.9~~$1.4 million increase in ~~clinical expenditures due to increased program activity, a $0.4 million increase in~~headcount related expenses, including stock-based compensation ~~expense due to an increase~~expense. It was partially offset by a $0.8 million decrease in ~~headcount, $0.2 million in milestone payments to two Stanford University inventors,~~outside services, including consulting and ~~a $0.2 million increase in facility and insurance expenses related to increase in operating activity.~~advisory services.

~~General~~Selling, general and administrative expenses ~~decreased~~increased by ~~$0.4~~$2.8 million to ~~$9.2~~$17.9 million for the nine months ended September 30, ~~2017~~2021, from ~~$9.6~~$15.1 million for the same period in ~~2016.~~2020. The ~~decrease~~increase was primarily due to a ~~$2.4~~$1.7 million increase in outside services, including consulting and advisory services, and a $1.3 million increase in headcount related expenses, including stock-based compensation expense, partially offset by a $0.2 million decrease in ~~legal, consulting, advisory~~sales and accounting services due to the incremental expenses incurred as a result of the Merger in the first quarter 2016. The decrease was partially offset by $1.1 million increase in stock-based compensation expense and a $0.6 million increase in compensation and personnel related expenses due to an increase in headcount, a $0.2 million increase in facility and insurance expenses and a $0.1 million increase in franchise tax expense due to increased operating activity.marketing expenses.

Interest ~~expense increased~~income decreased by ~~$0.4~~$0.5 million to ~~$1.1~~$0.1 million for the nine months ended September 30, ~~2017~~2021 from ~~$0.7~~$0.6 million for the same period in 2016. Interest expense in 2017 consisted of interest and amortization of the debt discount related to the Oxford Loan borrowings in December 2016. Interest expense in 2016 consisted of interest and amortization of the debt discount related to the Notes outstanding prior to their conversion into common stock in March 2016.

~~Interest income increased by $0.3 million for the nine months ended September 30, 2017,~~2020. The decrease was primarily due to ~~the~~a decrease in interest ~~earned~~rates on ~~our investments in marketable securities~~money market funds and ~~cash equivalents. There was no interest income earned for the nine months ended September 30, 2016, as funds were not invested until the fourth quarter in 2016.~~available-for-sale securities.

Other income, ~~(expense),~~ net increased by ~~$0.6~~$46.5 million compared to ~~$0.2 million of other income, net for the nine months ended September 30, 2017 from $0.4 million of other expense, net for~~ the same period in ~~2016. Other income in 2017~~2020. The increase was primarily ~~consisted of the payment~~due to net proceeds received from ~~Theragene~~the sale of our rare pediatric disease priority review voucher to AbbVie Inc., which closed in January 2021.

Provision for income taxes increased by $46,000 compared to the same period in 2020. The increase was primarily due to the tax expense ~~in 2016 primarily consisted of the change in fair value of the obligation~~related to ~~issue common stock to Eiccose and the change in fair value of warrant liability, that were settled upon the Merger.~~state taxes.

As of September 30, ~~2017,~~2021, we had ~~$13.1~~$85.3 million of cash, cash equivalents and short-term debt securities, comprised of $49.3 million of cash and cash equivalents ~~$19.3~~and $36.0 million of ~~marketable~~short-term debt securities available-for-sale, and an accumulated deficit of ~~$107.9~~$318.6 million. In addition, as of September 30, 2021, we had $35.1 million of long-term debt securities available-for-sale.

On ~~October 31, 2017,~~December 18, 2020, we ~~issued 2,132,961 shares of common stock pursuant~~filed a new shelf registration statement on Form S-3 (File No. 333-251497) with the Securities and Exchange Commission, which permits the offering, issuance and sale by us up to ~~an underwriting agreement with BTIG, LLC at~~ a ~~public~~maximum aggregate offering price of ~~$10.00 per share, for gross proceeds~~ $200.0 million of ~~$21,329,610, which resulted in approximately $19.5~~our common stock, preferred stock, debt securities and warrants. Up to a maximum of $50.0 million of ~~net proceeds~~the maximum aggregate offering price of $200.0 million may be issued and sold pursuant to ~~the Company after deducting underwriting fees and offering expenses.~~ a new ATM financing facility under a sales agreement with Jefferies. We have not issued any shares under this facility.

We believe that the currently available resources will be sufficient to fund our planned operations for at least the next 12 months following the issuance date of these unaudited condensed consolidated financial statements. However, if our anticipated operating results are not achieved in future periods, we believe that planned expenditures may need to be reduced ~~in order to extend the time period over which the then-available resources~~or we would be ~~able~~required to raise funding in order to fund our operations. Additionally, our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic.

Our primary uses of cash are to fund operating expenses, including research and development expenditures and selling, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in outstanding accounts payable and accrued expenses.

~~We have~~Prior to 2021, we had not generated any ~~revenue from~~ product ~~sales.~~revenue. We ~~do not know when, or if, we will generate any revenue from~~launched our first commercial product, ~~sales.~~Zokinvy, in January 2021. We ~~do not expect to generate any revenue from product sales unless and until we obtain regulatory approval for and commercialize any of our product candidates. At the same time, we~~ expect our expenses to increase in connection with our ongoing development and manufacturing activities, particularly as we continue the research, development, manufacture and clinical trials of, and seek regulatory approval for our product candidates.

Our primary uses of capital are, and we expect will continue to be, funding ~~research efforts and~~ the development of our product candidates, sales and marketing costs for commercialization of Zokinvy and our other product candidates, compensation and related expenses, hiring additional staff, including clinical, scientific, operational, financial, and management personnel, and costs associated with operating as a public company. We expect to incur substantial expenditures in the foreseeable future for the development and potential commercialization of our product candidates.

We plan to continue to fund losses from operations and capital funding needs through future equity and/or debt financings, as well as potential additional collaborations or strategic partnerships with other companies. As a result of economic conditions, general global economic uncertainty, political change and other factors, including the ongoing COVID-19 pandemic, we do not know whether additional capital will be available when needed, or that, if available, we will be able to obtain additional capital on reasonable terms. If we are unable to raise additional capital due to the volatile global financial markets, general economic uncertainty or other factors, we may need to curtail planned development or commercialization activities. The sale of additional equity or convertible debt could result in additional dilution to our stockholders. The incurrence of indebtedness would result in debt service obligations and could result in operating and financing covenants that would restrict our operations. We can provide no assurance that financing will be available in the amounts we need or on terms acceptable to us, if at all. If we are not able to secure adequate additional funding we may be forced to delay, make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially harm our business.

The following table summarizes our cash flows for the periods indicated (in thousands):

Cash used in operating activities for the nine months ended September 30, ~~2017~~2021 was ~~$28.0~~$54.6 million, ~~consisting~~which primarily consisted of a net loss of ~~$31.6~~ $12.1million, a $46.5 million gain from sale of priority review voucher and $0.3 million income related to asset purchase agreement which ~~was~~were partially offset by stock-based compensation expense of ~~$3.2~~$5.9million, non-cash interest expense of $0.6million, amortization of debt securities premiums and discounts of $0.7 million, amortization of operating lease right-of-use assets of $0.4 million, depreciation and amortization of $0.2 million, and common stock issued under Product Development Agreement of $0.2 million. Additionally, cash used in operating activities reflected changes in net operating assets ~~and liabilities primarily~~of $3.6 million due to an increase of ~~$1.5~~$2.5 million in inventories, an increase of $2.8 million in accounts ~~payable. The~~receivable, a decrease of $0.4 million in operating lease liabilities, and an increase ~~was~~of $0.8 million in other assets, partially offset by ~~$1.1~~an overall increase of $2.4 million ~~decrease~~ in accounts payable and accrued ~~and other~~ liabilities ~~associated with~~primarily due to the timing of ~~payments.~~payments, and by a decrease of $0.5 million in prepaid expenses and other current assets.

Cash used in operating activities for the nine months ended September 30, ~~2016~~2020 was ~~$26.8~~$47.7 million, which primarily ~~consisting~~consisted of a net loss of ~~$34.3~~$46.2 million, partially offset by ~~$3.2 million expense related to a non-cash issuance of common stock to Bristol-Meyers Squibb in connection with the BMS License Agreement, $1.8 million of~~ stock-based compensation expense ~~$0.7~~of $4.5 million, of non-cash interest expense ~~related to the convertible promissory notes outstanding prior to their conversion into~~of $0.6 million, amortization of operating lease right-of-use assets of $0.4 million and common stock ~~in March 2016 and $0.4 million change in fair value~~issued under Product Development Agreement of ~~warrant liability and obligation to issue shares to Eiccose.~~$0.2 million. Additionally, cash used in operating activities reflected changes in net operating assets ~~and liabilities primarily~~of $7.2 million due to an increase of ~~$1.6~~$4.4 million in prepaid expenses and other current assets primarily due to the timing of payments, an increase of $1.3 million in other assets primarily related to long term deposits with clinical research organizations, a decrease of $1.1 million in accounts payable and accrued liabilities due to timing of payments and ~~other liabilities primarily associated with increase~~a decrease of $0.4 million in ~~business activity.~~operating lease liabilities.

Cash ~~provided by~~ used in investing activities was ~~$13.1~~$74.9 million for the nine months ended September 30, ~~2017, and~~2021, primarily ~~consisted~~consisting of ~~$35.5~~$99.6 million of proceeds from maturities of ~~marketable~~debt securities, $46.5 million of net proceeds received from the sale of our priority review voucher, and $0.2 million of proceeds ~~from MYDICAR sale,~~pursuant to our asset purchase agreement with Theragene, which ~~was~~were partially offset by ~~$22.5~~$71.4 million ~~purchase~~ of ~~marketable~~purchases of debt securities.

Cash ~~provided by~~used in investing activities was $17.8 million for the nine months ended September 30, ~~2016~~2020, primarily ~~resulted from the $28.0~~consisting of $92.5 million of ~~cash received upon the consummation~~purchases of ~~the Merger.~~debt securities, partially offset by $74.8 million of proceeds from maturities of debt securities.

Cash provided by financing activities for the nine months ended September 30, ~~2017~~ 2021 primarily consisted of $0.5 million of proceeds from the ~~purchase~~issuance of common stock ~~under our ESPP.~~upon stock option exercises and ESPP purchases, partially offset by $0.2 million payments for debt issuance costs and $0.2 million payments for deferred offering costs.

Cash provided by financing activities for the nine months ended September 30, ~~2016~~2020 primarily consisted of ~~$32.1~~$77.4 million of net proceeds from the issuance of common stock upon offering at-the-market and $0.7 million of proceeds from the issuance of common stock ~~in the private placement, net of issuance costs,~~ upon stock option exercises and net proceeds of $18.2 million from the issuance of common stock in the underwritten public offering on August 23, 2016, after deducting underwriting discounts and commissions and expenses payable by us.ESPP purchases.

~~The following table summarizes our~~Our contractual obligations atas of September 30, 2021 have not materially changed from what we presented in our Annual Report on Form 10-K for the year ended December 31, ~~2016 (in thousands):~~

In March 2017, we entered into a non-cancelable facility lease agreement for an office facility in Palo Alto, California. The lease commenced on April 1, 2017 and expires 12 months after the commencement date. The lease has one 12-month renewal option prior to expiration and includes rent escalation clauses through the lease term. In April 2017, we provided a security deposit of $27,000 as collateral for the lease. The ~~operating lease obligation amounts above do not reflect our future minimum rent payable under the new lease agreement of approximately $0.3 million during the next year.~~

We are obligated to make future payments to third parties under asset purchase and license agreements, including royalties and payments that become due and payable on the achievement of certain development and commercialization milestones. We have not included these potential payment obligations in the table above as the amount and timing of such payments are not known.9, 2021.

During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under the rules of the SEC and do not have any holdings in variable interest entities.

~~As of September 30, 2017, we had market risk exposure related to our cash and cash equivalents.~~ We ~~had cash and cash equivalents of $13.1 million and $19.3 million of short-term marketable securities. Such interest-earning instruments carry~~are a degree of interest rate risk; however, historical fluctuations of interest income have not been significant. We have not been exposed nor do we anticipate being exposed to material risks due to changes in interest rates. A hypothetical 10% change in interest rates during anysmaller reporting company as defined by Rule 12b-2 of the ~~periods presented would~~Securities Exchange Act of 1934 and are not ~~have had a material impact on our unaudited condensed consolidated financial statements.~~

~~Financial instruments that potentially subject us~~required to concentration of credit risk consist of cash and cash equivalents. We place our cash and cash equivalents with high credit quality financial institutions and pursuant to our investment policy, we limitprovide the amount of credit exposure with any one financial institution. Deposits held with banks may exceed the amount of insurance provided on such deposits. We have not experienced any losses on our deposits of cash and cash equivalents.

We carry out some of our clinical development and supportive activities in foreign countries and payments may be due in foreign currencies. We do not participate in any foreign currency hedging activities and we do not have any other derivative financial instruments. We did not recognize any significant exchange rate losses during the three and nine months ended September 30, 2017.information under this item.

~~Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our~~We are responsible for maintaining disclosure controls and procedures, ~~(as~~as defined in Rules 13a-15(e) and 15d-15(e) under the ~~Securities~~Exchange Act. Disclosure controls and procedures are controls and other procedures designed to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Based on our management’s evaluation (with the participation of ~~1934,~~our principal executive officer and our principal financial officer) of our disclosure controls and procedures as ~~amended),~~required by Rule 13a-15 under the Exchange Act, our principal executive officer and our principal financial officer have concluded that our disclosure controls and procedures were effective to achieve their stated purpose as of September 30, 2021, the end of the period covered by this ~~Quarterly~~report.

Management’s Report on ~~Form 10-Q.~~Internal Control over Financial Reporting.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Exchange Act Rule 13a-15(f). Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, to provide reasonable assurance, not absolute assurance, regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.

There are inherent limitations to the effectiveness of any system of internal control over financial reporting. These limitations include the possibility of human error, the circumvention or overriding of the system and reasonable resource constraints. Because of its inherent limitations, our internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

As of September 30, 2021, our management assessed the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013 Framework). Based on ~~such evaluation,~~this assessment, our ~~Chief Executive Officer and Chief Financial Officer have~~management concluded that, as of ~~the end of the period covered by this quarterly report,~~September 30, 2021, our ~~disclosure controls and procedures were, in design and operation, effective.~~internal control over financial reporting was effective based on those criteria.

~~There~~Except as otherwise described above under Management’s Report on Internal Control over Financial Reporting, there were no ~~material~~ changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the ~~three and nine months~~fiscal quarter ended September 30, ~~2017,~~2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

In designing and evaluating the disclosure controls and procedures and internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

~~See Note 9~~From time to time we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that in the opinion of our management, if determined adversely to us, would have a material adverse effect on our business, financial condition, operating results or cash flows. Regardless of the ~~Notes to the unaudited Condensed Consolidated Financial Statements contained within this Quarterly Report~~outcome, litigation can have an adverse impact on ~~Form 10-Q for a further discussion~~us because of ~~our legal proceedings.~~defense and settlement costs, diversion of management resources and other factors.

You should carefully consider the following risk factors, as well as the other information in this Quarterly Report on Form 10-Q, and in our other public filings. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this Quarterly Report on Form ~~10-Q~~10Q and those we may make from time to time. You should consider all of the risk factors described when evaluating our business. ~~We have marked with~~

Below is a summary of material factors that make an ~~asterisk (*) those risk factors below that reflect significant changes from the risk factors included~~investment in our ~~Annual~~common stock speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face. Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face, can be found in the “Risk Factors” section of this Quarterly Report on Form ~~10-K for~~10-Q. The below summary is qualified in its entirety by that more complete discussion of such risks and uncertainties. You should consider carefully the ~~year ended December 31, 2016.~~risks and uncertainties described further below as part of your evaluation of an investment in our common stock.

We have incurred losses since our inception, have a limited operating history on which to assess our business, and anticipate that we will continue to incur significant losses for the foreseeable future.*

We are a clinical development-stage biopharmaceutical company with a limited operating history. We have incurred net losses in each year since our inception. For the nine months ended September 30, ~~2017~~2021 and ~~2016,~~2020, we reported a net loss of ~~$31.6~~$12.1 million and ~~$34.3~~$46.2 million, respectively. As of September 30, ~~2017,~~2021, we had an accumulated deficit of ~~approximately $107.9~~$318.6 million. Our prior losses, combined with expected future losses, have had and may continue to have an adverse effect on our stockholders’ equity and working capital.

We believe that ~~the~~our currently available resources will be sufficient to fund our planned operations for at least the next 12 months following the issuance date of these ~~unaudited condensed~~ consolidated financial statements. We will continue to require substantial additional capital to continue our clinical development, manufacturing and regulatory approval efforts and potential commercialization activities. Accordingly, we will need to raise substantial additional capital to continue to fund our operations. The ~~amount~~amounts and timing of our future funding requirements will depend on many factors, including our ability to achieve regulatory approval and the pace and results of our clinical development efforts. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop our product candidates.

We have devoted substantially all of our financial resources to identify, acquire, and develop our product candidates, including manufacturing of clinical supplies, conducting clinical studies and providing selling, general and administrative support for our operations. To date, we have financed our operations primarily through the sale of equity securities and debt facilities. The amount of our future net losses will depend, in part, on the rate of our future expenditures and our ability to obtain funding through equity or debt financings, strategic collaborations, or grants. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We expect losses to increase as regulatory review of our MAA of Zokinvy for treatment of Progeria and processing-deficient progeroid laminopathies progresses towards potential approval and as we advance ~~five Phase 2~~our clinical development programs ~~for potentially four indications. While we have not yet commenced pivotal~~in various clinical studies, particularly the D-LIVR pivotal study, to support the submission of an NDA for ~~any product candidate and it~~lonafarnib for use in an HDV indication. We may need significant additional resources in order to aggressively move lonafarnib forward successfully based on the discussions with the FDA. It may be several years, if ever, before we complete pivotal clinical studies and have aadditional product ~~candidate~~candidates approved for ~~commercialization, we~~commercialization. We expect to invest significant funds into ~~these~~our clinical candidates ~~to determine the potential~~ to advance these compounds to potential regulatory approval.

If we obtain regulatory approval to market aone or more additional product ~~candidate,~~candidates, our future revenue will depend upon the size of any markets in which our product candidates may receive approval, and our ability to achieve sufficient market acceptance, pricing, reimbursement from third-party payors, and adequate market share for our product candidates in those markets. Even if we obtain adequate market share for our product candidates, because the potential markets in which our product candidates may ultimately receive regulatory approval could be very small, we may never become profitable despite obtaining such market share and acceptance of our products. We have also agreed with The Progeria Research Foundation to make Zokinvy available to Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient progeroid laminopathies patients under an expanded access program that may not result in payment to us.

We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future and our expenses will increase substantially if and as we:

Further, the net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a representative indication of our future performance.

WePrior to 2021, we have never generated any ~~revenue from~~ product ~~sales~~revenue and may never be profitable.

We have ~~no products~~one product approved for commercialization in the U.S. for two ultra-rare diseases. Zokinvy to reduce the risk of mortality in Progeria, and ~~have never generated any revenue.~~for treatment of processing-deficient progeroid laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation, or homozygous or compound heterozygous ZMPSTE24 mutations, was approved by the FDA in November 2020 and launched commercially in the U.S. in January 2021. Our ability to generate substantial revenue and achieve profitability depends on our ability, alone or with strategic collaboration partners, to obtain the regulatory and marketing approvals necessary to commercialize Zokinvy in foreign jurisdictions and to successfully complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize, ~~one or~~ more of our product ~~candidates.~~candidates in the U.S. or foreign jurisdictions. We do not anticipate generating ~~revenue from~~significant product ~~sales~~revenue for the foreseeable future. Our ability to generate future ~~revenue from~~ product ~~sales~~revenue depends heavily on our success in many areas, including but not limited to:

Even if ~~one or more of the~~we obtain additional product ~~candidates that we develop is approved~~approvals for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our current pipeline of product candidates has been in-licensed from third parties and we will have to develop or acquire manufacturing capabilities in order to continue development and potential commercialization of our product candidates. Additionally, if we are not able to generate sufficient revenue from the sale of any approved products, we may never become profitable.

Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights.

To the extent that we raise additional capital through the sale of equity, debt or other securities convertible into equity, your ownership interest will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect your rights as a common stockholder such as the ~~debt facility~~Loan and Security Agreement we entered into with Oxford Finance LLC (Oxford Finance) in December ~~2016. This~~2016 (the Oxford Loan). The Oxford Loan was a $25.0 million debt financing arrangement with Oxford Finance wherein we borrowed the first tranche of $15.0 million upon closing of the debt financing in December 2016. ~~Our ability~~In May 2018, we entered into an amendment to ~~access~~the Oxford Loan and borrowed $5.0 million. In August 2018, we drew the final ~~$10.0~~$5.0 million ~~under the loan and security agreement is subject to our ability to achieve~~upon achievement of certain clinical ~~development milestones,~~milestones. In March 2019, we entered into the third amendment to the Oxford Loan to refinance our outstanding principal balance of $23.3 million. Upon refinancing, the Oxford Loan was increased to $35.0 million in aggregate commitments, of which ~~we may not be able to meet and which and could adversely affect our liquidity.~~$30.0 million in principal is outstanding. The ~~loan~~Oxford Loan is secured by ~~the~~ perfected first priority liens on ~~the Company's~~our assets, excluding intellectual property but including a commitment by ~~the Company~~us to not allow any liens to be placed upon ~~the Company’s~~such intellectual property. The Oxford Loan includes customary events of default, including failure to pay amounts due, breaches of covenants and warranties, material adverse effect events, certain cross defaults and judgments, and insolvency. If the Company is unable to comply with these covenants or if the Company default on any portion of the outstanding borrowings, the lenders can also impose a 5.0% penalty and restrict access to additional borrowings under the loan and security agreement.

If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates or future revenue streams or grant licenses on terms that are not favorable to us. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. We cannot assure you that ~~we will~~ we will be able to obtain additional funding if and when necessary to fund our entire portfolio of product candidates to meet our projected plans. If we are unable to obtain funding on a timely basis, we may be required to delay or discontinue one or more of our development programs or the commercialization of any product candidates or be unable to expand our operations or otherwise capitalize on potential business opportunities, which could materially affect our business, financial condition, and results of operations.

Covenants in ~~our loan and security agreement~~the Oxford Loan restrict our business and operations in many ways and if we do not effectively ~~manage~~comply with our covenants, our financial conditions and results of operations could be adversely affected. In addition, we may not meet the milestones required to access the final loan available under the agreement and may also not provide sufficient cash to meet the repayment obligations of our debt incurred under the loan and security agreement.

~~Our loan and security agreement with~~The Oxford ~~Finance LLC~~Loan provides for up to ~~$25.0~~$35.0 million in term loans due on ~~July~~March 1, ~~2021,~~2024, of which ~~$15.0~~$30.0 million in ~~term loans has been borrowed to date.~~principal is outstanding. All of our current and future assets, except for intellectual property, ~~are secured for~~secure our borrowings under the ~~loan and security agreement.~~Oxford Loan. The ~~loan and security agreement~~Oxford Loan requires that we comply with certain covenants applicable to us, including among other things, covenants restricting dispositions, changes in business, management, ownership or business locations, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt, any of which could restrict our business and operations, particularly our ability to respond to changes in our business or to take specified actions to take advantage of certain business opportunities that may be presented to us. Our failure to comply with any of the covenants could result in a default under the ~~loan and security agreement,~~Oxford Loan, which could permit the lenders to declare all or part of any outstanding borrowings to be immediately due and ~~payable, or to refuse to permit additional borrowings under the loan and security agreement.~~payable. If we are unable to repay those amounts, the lenders under the ~~loan and security agreement~~Oxford Loan could proceed against the collateral granted to them to secure that debt, ~~which~~and our inability to use or dispose of those assets would seriously harm our business. In addition, should we be unable to comply with these covenants or if we default on any portion of our outstanding borrowings, the lenders can also impose a 5.0% penalty, ~~and~~ restrict access to additional borrowings under the loan and security ~~agreement. Moreover, our ability to access~~agreement, and accelerate the ~~final $10.0 million~~maturity of the debt. Any default under the ~~loan and security agreement is subject to our ability to achieve certain clinical development milestones, which we may not be able to meet and which and could adversely~~Oxford Loan would materially affect our liquidity. In addition, although we expect to borrow additional funds under the loan and security agreement, before we do so, we must first satisfy ourselves that we will have access to future alternate sources of capital, including cash flow from our own operations, equity capital markets or debt capital markets in order to repay any principal borrowed, which we may be unable to do, in which case, our liquidity and ability to fund our operations ~~may~~and complete our planned clinical trials and regulatory filings would be substantially impaired.

If the London Inter-Bank Offered Rate, or LIBOR, is discontinued, interest payments under the Oxford Loan may be calculated using another reference rate.

In July 2017, the Chief Executive of the United Kingdom Financial Conduct Authority (FCA), which regulates LIBOR, announced that the FCA intends to phase out the use of LIBOR by the end of 2021. In addition, the U.S. Federal Reserve, in conjunction with the Alternative Reference Rates Committee, a steering committee comprised of large U.S. financial institutions, is considering replacing U.S. dollar LIBOR with the Secured Overnight Financing Rate, or SOFR, a new index calculated by short-term repurchase agreements, backed by Treasury securities. LIBOR is used as a benchmark rate throughout the Oxford Loan. On October 6, 2021, we entered into the sixth amendment to the Oxford Loan (the Sixth Amendment) to replace the LIBOR benchmark rate with the LIBOR replacement rate upon a LIBOR transition event, as discussed more fully in Note 13 to the unaudited condensed consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q. While we do not currently expect the impact of this change to be material, there remains uncertainty regarding the future utilization of LIBOR and the nature of any replacement rate, including the LIBOR replacement rate under the Sixth Amendment, and any potential effects of the transition away from LIBOR on us are not fully known. The transition process may involve, among other things, increased volatility and illiquidity in markets for instruments that currently rely on LIBOR and may result in increased borrowing costs, the effectiveness of related transactions such as hedges, or uncertainty under applicable documentation, including the Oxford Loan. As a result, our ability to refinance our credit agreement or other indebtedness or to hedge our exposure to floating rate instruments may be impaired, which would adversely affect the operations of our business.

We are ~~heavily~~ dependent on the success of our product candidates, which are in ~~the early~~various stages of clinical development. Certain of our product candidates have produced results in academic settings to date or for other indications than those that we contemplate, and we cannot give any assurance that we will generate data for any of our product candidates sufficient to receive regulatory approval in our planned indications, which will be required before they can be commercialized.*

To date, we have invested substantially all of our efforts and financial resources to identify, acquire, and develop our portfolio of product candidates. Our future success is dependent on our ability to ~~successfully~~ further develop, obtain regulatory ~~approval~~approvals for, and commercialize one or more of these product candidates. WeOur NDA for Zokinvy to reduce the risk of mortality in Progeria, and for treatment of processing-deficient progeroid laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation, or homozygous or compound heterozygous ZMPSTE24 mutations, was approved in November 2020. Our MAA is currently ~~generate~~under standard review with the EMA and we recently received feedback from the CHMP with respect to our pending MAA requesting additional information relating to the demonstration of efficacy for Zokinvy. While we intend to work closely with the CHMP to address this feedback, we cannot be certain of the timing or outcome of such interactions. In addition, if the EMA rejects our MAA or we decide to withdraw our application, we may no longer be eligible for reimbursement in France for the use of Zokinvy under the ATU program. Prior to the U.S. Zokinvy commercial launch in 2021, we had not generated revenue from sales of any drugs and we may never be able to develop or commercialize additional product candidates. In addition, we have a ~~product candidate.~~commitment to provide access to Zokinvy for patients with Progeria and processing-deficient progeroid laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation, or homozygous or compound heterozygous ZMPSTE24 mutations, for no or minimal cost to those patients.

WeWith respect to potential commercial products, we currently have ~~five~~two product candidates that are in Phase 23 clinical development or entering Phase 3 and two development programs focused on ~~four~~two separate ~~indications. For one of our product candidates, ubenimex, data to date has been developed for use in~~ indications ~~other than those~~ that have we believe have ~~rights to or in which we plan to develop the product candidate~~completed Phase 2 and most of the data has been developed for a dose lower than in our current studies. Similarly, some of our lonafarnib results to date rely on an assay that has not been validated or accepted by the FDA to assess the potential efficacy of the product. While we have undertaken confirmation with an European Medical Agency approved assay, there can be no assurance that the data we have seen to dateare advancing towards Phase 3. It may be ~~replicated in a FDA validated assay,~~years before our studies are initiated and completed, if ~~available.~~at all.

We provide our geographically diverse clinical sites with good clinical practice protocols. We review and monitor the execution of our protocols at our various sites in an effort to understand those protocols are being followed. There can be no assurance that the data we develop for our product candidates in our planned indications will be sufficient or complete enough to obtain regulatory approval.

We may not be able to obtain FDA approval of any future NDA or BLA for our product candidates.

The clinical development, manufacturing, labeling, packaging, storage, recordkeeping, advertising, promotion, export, import, marketing and distribution and other possible activities relating to lonafarnib, peginterferon lambda, avexitide and any other product candidate that we may develop in the future are subject to extensive regulation in the United States. Prior to the approval of our NDA for Zokinvy to reduce the risk of mortality in Progeria, and for treatment of processing-deficient progeroid laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation, or homozygous or compound heterozygous ZMPSTE24 mutations, we had not submitted an application for approval or obtained FDA approval for any product.

Approval of an NDA or a BLA is not guaranteed, and the approval process is an expensive and uncertain process that may take several years. The FDA and foreign regulatory entities also have substantial discretion in the approval process. The number and types of preclinical studies and clinical trials that will be required for approval varies depending on the product candidate, the disease or the condition that the product candidate is designed to target and the regulations applicable to any particular product candidate. Data are subject to varying interpretation and the FDA may not agree that our clinical data support that any of our product candidates are safe and effective for the proposed therapeutic use. Despite the time and expense associated with preclinical studies and clinical trials, failure can occur at any stage, and we could encounter problems that require us to repeat or perform additional preclinical studies or clinical trials or generate additional chemistry, manufacturing and controls data, including drug product stability data. In previous studies, ECG abnormalities were observed in our lonafarnib program. We do not expect that this will impact the conduct of the D-LIVR HDV study. The FDA and similar foreign authorities could delay, limit or deny approval of a product candidate, and may ultimately approve the product for narrower indications or with unfavorable labeling that would impede our commercialization of the drug.

Approval procedures vary among countries and can involve additional product testing and additional administrative review periods, including obtaining reimbursement and pricing approval in select markets. The time required to obtain approval in other countries might differ from that required to obtain FDA approval. The regulatory approval process in other countries may include all of the risks associated with FDA approval as well as additional, presently unanticipated, risks. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others, including the risk that our product candidates may not be approved for all indications requested and that such approval may be subject to limitations on the indicated uses for which the product may be marketed.

Our business strategy is based upon obtaining ~~orphan drug~~and maintaining Orphan Drug designation for our product candidates, which is an uncertain process. The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, and inherently unpredictable. If we are unable to obtain ~~orphan drug~~Orphan Drug designation or regulatory approval for our product candidates, our business ~~will~~would be substantially harmed.*

Our approach to identifying and developing product candidates depends, in large part, on our ability to obtain ~~orphan drug~~and maintain Orphan Drug designation from regulatory authorities in major markets. Without the potential protection of this regulatory exclusivity upon approval, many of our product candidates would otherwise not justify investment. In addition, the Company actively pursues new patents on all product candidates, such as the patent already issued covering PAH, that could potentially extend the market exclusivity beyond the available exclusivity provided by the orphan indication. While we assess the potential for obtaining ~~orphan drug~~Orphan Drug designation at the time that we contemplate the acquisition of product candidates and we intend to timely file for such designation, there can be no assurance that we will obtain ~~orphan drug~~Orphan Drug designation or be able to successfully meet the regulatory requirements to maintain that designation with the planned clinical trials for our product candidates. Failure to obtain ~~orphan drug~~and maintain Orphan Drug designation would make our product candidates significantly less competitive and potentially not viable investments for further development. Although we ~~already obtained orphan drug~~currently have Orphan Drug designation for ~~four~~some of our product candidates in ~~three~~multiple targeted indications, failure to demonstrate significant benefit over existing approved drugs in pivotal clinical trials may lead to marketing approval but without qualifying for ~~orphan drug~~Orphan Drug protection in some regions, such as in Europe.

The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable, typically takes many years following the commencement of clinical studies and depends upon numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. We have ~~not~~ obtained U.S. regulatory approval for ~~any~~one product, ~~candidate,~~Zokinvy, and it is possible that none of our ~~existing~~current product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.

~~Applications~~Future applications for our product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following:

The lengthy and uncertain regulatory approval process, as well as the unpredictability of the results of clinical studies, may result in our failing to obtain additional regulatory approval to market any of our product candidates or to be significantly delayed from our expectations for potential approval, which would significantly harm our business, results of operations, and prospects.In addition, although we have obtained ~~orphan drug~~Orphan Drug designation for ~~four~~five of our ~~product candidates in our planned indications~~development programs to date, there can be no assurance that the FDA will grant our similar status for our other proposed development indications or other product candidates in the future.

Although the FDA has granted Rare Pediatric Disease Designation to avexitide for the treatment of congenital hyperinsulinism, BLA approval for this program may not meet the eligibility criteria for a priority review voucher.

Our avexitide compound has received Rare Pediatric Disease (RPD) designation from the FDA for the treatment of Congenital Hyperinsulinism (HI). The FDA defines a “rare pediatric disease” as a serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect patients under the age of 18 years, that is a rare disease or condition, that is, a disease or condition that affects fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug in the United States will be recovered from sales in the United States for that drug or biological product. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a “rare pediatric disease” may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application. The FDA may also revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed in the U.S. within one year following the date of approval. In addition, the priority review voucher is only awarded to an NCE, thus if a compound is approved first for an indication that is not a rare pediatric disease the compound may not be eligible to receive the voucher. While we obtained and sold the priority review voucher issued upon approval of Zokinvy to reduce the risk of mortality in Progeria, and for treatment of processing-deficient progeroid laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation, or homozygous or compound heterozygous ZMPSTE24 mutations, and processing-deficient progeroid laminopathies, there can be no assurance that we will be successful in obtaining approval for avexitide for the treatment of HI, or that a priority review voucher will be issued at the time of any such approval.

Congress has only authorized the rare pediatric disease priority review voucher program until September 30, 2024. However, if a drug candidate receives RPD designation before September 30, 2024, it is eligible to receive a voucher if it is approved before September 30, 2026.Avexitide may not be approved by that date, or at all, and, therefore, we may not be in a position to obtain a priority review voucher prior to expiration of the program, unless Congress further reauthorizes the program.

There is no assurance we will receive a rare pediatric disease priority review voucher. Also, although priority review vouchers may be sold or transferred to third parties, there is no guarantee that we will be able to realize any value if we were to sell a priority review voucher.

Although we have received Breakthrough Therapy designations, this may not lead to a faster development, regulatory review or approval process, and it does not increase the likelihood of receiving marketing approval in the United States.

We have received Breakthrough Therapy designation for lonafarnib and peginterferon lambda for the treatment of HDV, and for avexitide for the treatment of post-bariatric hypoglycemia and congenital hyperinsulinism. A breakthrough therapy is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For therapies that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Therapies designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval.

Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. The Breakthrough Therapy designations we have obtained may not result in faster development processes, reviews or approvals compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, the FDA may later decide that any of our development programs no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product no longer meets the conditions for qualification. Thus, even though we intend to seek Breakthrough Therapy designation for and some or all of our future product candidates for the treatment of various cancers, there can be no assurance that we will receive breakthrough therapy designation.

Drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not be predictive of future study results.*

Clinical testing is expensive and generally takes many years to complete, and the outcome is inherently uncertain. Failure can occur at any time during the clinical study process. The results of preclinical studies and early clinical studies of our product candidates may not be predictive of the results of larger, later-stage controlled clinical studies. Product candidates that have shown promising results in early-stage clinical studies may still suffer significant setbacks in subsequent clinical studies. Our clinical studies to date have been conducted on a small number of patients in limited numbers of clinical sites and in academic settings or for other indications. We will have to conduct larger, well-controlled studies in our proposed indications to verify the results obtained to date and to support any regulatory submissions for further clinical development. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical studies due to lack of efficacy or adverse safety profiles despite promising results in earlier, smaller clinical studies. Moreover, clinical data are often susceptible to varying interpretations and analyses. We do not know whether any Phase 2, Phase 3, or other clinical studies we have conducted or may conduct will demonstrate consistent or adequate efficacy and safety with respect to the proposed indication for use sufficient to obtain regulatory approval to receive regulatory approval or market our drug candidates. For example, in 2018 we ~~identified significant GCP violations~~announced negative results from two of our Phase 2 clinical trials of ubenimex in ~~the LOWR HDV – 1~~two different indications and ~~LOWR HDV – 2 studies. We alerted the FDA to the discovery~~as a result we have terminated further development of GCP violations. These findings may call into question the validity of the data set and may require repeat clinical studies to confirm the observations in question. Further studies may be needed to confirm the rigor, robustness and validity of any problematic safety and efficacy data identified.ubenimex.

We may find it difficult to enroll patients in our clinical studies given the limited number of patients who have the diseases for which our product candidates are being studied. Difficulty in enrolling patients could delay or prevent clinical studies of our product candidates.

Identifying and qualifying patients to participate in clinical studies of our product candidates is essential to our success. The timing of our clinical studies depends in part on the rate at which we can recruit patients to participate in clinical trials of our product candidates, and we may experience delays in our clinical studies if we encounter difficulties in enrollment.

The eligibility criteria of our planned clinical studies may further limit the available eligible study participants as we expect to require that patients have specific characteristics that we can measure or meet the criteria to assure their conditions are appropriate for inclusion in our clinical studies. We may not be able to identify, recruit, and enroll a sufficient number of patients to complete our clinical studies in a timely manner because of the perceived risks and benefits of the product candidate under study, the availability and efficacy of competing therapies and clinical studies, and the willingness of physicians to participate in our planned clinical studies. If patients are unwilling to participate in our clinical studies for any reason, the timeline for conducting studies and obtaining regulatory approval of our product candidates may be delayed.

If we experience delays in the completion of, or termination of, any clinical study of our product candidates, the commercial prospects of our product candidates could be harmed, and our ability to generate product revenue from any of these product candidates could be delayed or prevented. In addition, any delays in completing our clinical studies would likely increase our overall costs, impair product candidate development and jeopardize our ability to obtain regulatory approval relative to our current plans. Any of these occurrences may harm our business, financial condition, and prospects significantly.

Clinical studies are costly, time consuming and inherently risky, and we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.

Clinical development is expensive, time consuming and involves significant risk. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical studies can occur at any stage of development. Events that may prevent successful or timely completion of clinical development include but are not limited to:

Any inability to successfully complete clinical development and obtain regulatory approval could result in additional costs to us or impair our ability to generate revenue. Clinical study delays could also shorten any periods during which our products have patent protection and may allow competitors to develop and bring products to market before we do, which could impair our ability to obtain ~~orphan drug~~Orphan Drug designation exclusivity and to successfully commercialize our product candidates and may harm our business and results of operations.

Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.*

Undesirable side effects, or unforeseen side effects due to incomplete or inadequate safety data collection from LOWR HDV – 1 and LOWR HDV – 2 clinical studies, caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or terminate or conduct additional or larger clinical studies or even if approved, result in a restrictive label or delay regulatory approval by the FDA or comparable foreign authorities.

~~For example, our~~Our lonafarnib product candidate has been studied in thousands of oncology patients and the most common non-hematologic adverse events of any grade were gastrointestinal system disorders (nausea, anorexia, diarrhea and vomiting), weight loss, fatigue and rash. Use of Zokinvy to reduce the risk of mortality in Progeria, and for treatment of processing-deficient progeroid laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation, or homozygous or compound heterozygous ZMPSTE24 mutations, has been reported to cause ECG abnormalities, but these ECG abnormalities have not resulted in a risk of mortality for these patients. There is no guarantee that additional or more severe side effects or other properties will not be identified through ongoing clinical studies by other uses of lonafarnib for other indications or our own clinical trials. ~~Additionally, while we have a license~~Our peginterferon lambda product candidate is well-characterized and has been studied in thousands of HBV and HCV patients and the most common adverse events seen are moderate headache, pyrexia, fatigue, and myalgia. ALT flares that were seen result from vigorous antiviral immunological response to ~~another farnesyltransferase inhibitor compound, tipifarnib, from Janssen Pharmaceutica, N.V.,~~treatment, not due to direct hepatotoxicity. There is no guarantee that additional or ~~Janssen, Janssen has granted rights to tipifarnib to Kura Oncology, Inc., or Kura, in oncology and negative results or undesirable~~more severe side effects ~~from Kura’s~~will not be identified through ongoing clinical ~~trials~~studies for ~~a compound with a similar mechanism~~other uses of ~~action may negatively impact the perception of lonafarnib for anti-viral indications. Merck may also grant rights to other anti-viral or potentially other indications to other third parties.~~peginterferon lambda. Undesirable side effects, other properties, and negative results for other indications may negatively impact the development and potential for approval of our product candidates for our proposed indications. For example, the ECG abnormalities seen with lonafarnib in HGPS and PL patients has the potential to impact the labeling for lonafarnib combined with ritonavir for HDV.Our avexitide product candidate has been studied in 54 PBH patients and 39 HI patients and the most common adverse events are injection site bruising, nausea, and headache. There is no guarantee that additional or more severe side effects will not be identified through ongoing clinical studies for other uses of avexitide in clinical trials.

Additionally, even if one or more of our current product candidates receives marketing approval, and we or others later may identify undesirable side effects caused by such products, potentially significant negative consequences could result, including but not limited to:

Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, even if approved, and could significantly harm our business, results of operations, and prospects.

~~Even~~We are subject to ongoing regulatory requirements related to the U.S. approval of Zokinvy, and if we obtain additional regulatory ~~approval~~approvals for a product candidate, we will ~~remain~~be subject to additional ongoing regulatory requirements.

If our product candidates are approved, they will be subject to ongoing regulatory requirements with respect to manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy and other post-approval information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.

Manufacturers and manufacturers’ facilities are required to continuously comply with FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to current Good Manufacturing Practices ~~or cGMP,~~(cGMP) regulations and corresponding foreign regulatory manufacturing requirements. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA, ~~or marketing authorization application,~~BLA, or MAA.

Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product candidate may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase IV4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. We will be required to report certain adverse reactions and production problems, if any, to the FDA and comparable foreign regulatory authorities.

Any new legislation addressing drug safety issues could result in delays in product development or commercialization, or increased costs to assure compliance. If our original marketing approval for a product candidate was obtained through an accelerated approval pathway, we could be required to conduct a successful post-marketing clinical study ~~in order~~ to confirm the clinical benefit for our products. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval.

If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing, or labeling of a product, the regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:

Any government investigation of alleged violations of law would be expected to require us to expend significant time and resources in response and could generate adverse publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to develop and commercialize our products and the value of us and our operating results would be adversely affected.

We rely on third parties to conduct our clinical studies, manufacture our product candidates and perform other services. If these third parties do not successfully perform and comply with regulatory requirements, we may not be able to successfully complete clinical development, obtain regulatory approval or commercialize our product candidates and our business could be substantially harmed.*

We have relied upon and plan to continue to rely upon investigators and third-party CROs to conduct, monitor and manage our ongoing clinical programs. We rely on these parties for execution of clinical studies and manage and control only certain aspects of their activities. We remain responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We, our investigators, and our CROs and other vendors are required to comply all applicable laws, regulations and guidelines, including those required by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. If we or any of our investigators, CROs or vendors fail to comply with applicable laws, regulations and guidelines, the results generated in our clinical studies may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional studies before approving our marketing applications. For example, we identified significant GCP violations in the LOWR HDV – 1 and LOWR HDV – 2 studies. We alerted the FDA to the discovery or GCP violations. These findings may call into question the validity of the data set and may require repeat clinical studies to confirm the observations in question. Further studies may be needed to confirm the rigor, robustness and validity of any problematic safety and efficacy data identified. We cannot assure you that our CROs and other vendors will meet these requirements, or that upon inspection by any regulatory authority, such regulatory authority will determine that efforts, including any of our clinical studies, comply with applicable requirements. Our failure to comply with these laws, regulations and guidelines may require us to repeat clinical studies or conduct larger additional studies, which would be costly and delay the regulatory approval process.

If any of our relationships with investigators or third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs in a timely manner or do so on commercially reasonable terms. In addition, our CROs may not prioritize our clinical studies relative to those of other customers and any turnover in personnel or delays in the allocation of CRO employees by the CRO may negatively affect our clinical studies. If investigators or CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, our clinical studies may be delayed or terminated, and we may not be able to meet our current plans with respect to our product candidates. CROs may also involve higher costs than anticipated, which could negatively affect our financial condition and operations.

In addition, we do not currently have, nor do we plan to establish, the capability to manufacture product candidates for use in the conduct of our clinical studies or in support of our commercialization of potential products, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale without the use of third-party manufacturers. We plan to rely on third-party manufacturers and their responsibilities will include purchasing from third-party suppliers the materials necessary to produce our product candidates for our clinical studies and regulatory approval. There are expected to be a limited number of suppliers for the active ingredients and other materials that we expect to use to manufacture our product candidates, and we may not be able to identify alternative suppliers to prevent a possible disruption of the manufacture of our product candidates for our clinical studies, and, if approved, ultimately for commercial sale. Although we generally do not expect to begin a clinical study unless we believe we have a sufficient supply of a product candidate to complete the study, any significant delay or discontinuity in the supply of a product candidate, or the active ingredient or other material components in the manufacture of the product candidate, could delay completion of our clinical studies and potential timing for regulatory approval of our product candidates, which would harm our business and results of operations.

With respect to our lonafarnib program, we procured an inventory of product from Merck to supply our initial clinical study needs. In 2016, we transferred the manufacturing of drug substance and drug product to our third-party contractors. The material used for lonafarnib HDV pivotal trials, ongoing Progeria clinical studies and expanded access program, and commercial Zokinvy supply are sourced from Eiger-controlled CMOs. These same vendors are currently under development for commercial qualification. Materials used for our avexitide clinical trials are also sourced from CMOs. Our vendors have successfully made GMP batches for our ~~future~~ clinical studies. With respect to our lambda program, as part of the license agreement, we obtained a substantial inventory of product from BMS sufficient to initiate our clinical trials. During 2017 we transferred the manufacturing technology to our third-party vendors. With respect to our ubenimex programs we have relied on Nippon KayakuIf these CMOs are not able to provide us with ~~product to conduct our trials in 2016~~sufficient quantities of drug substance and ~~2017 and have now completed the process of transferring the manufacturing of ubenimex to our third-party vendors in the United States and such~~ drug product ~~will~~for our clinical trials or in support of our commercialization of potential products on a timely basis, or at all, whether due to production shortages or other supply interruptions resulting from the ongoing COVID-19 pandemic or otherwise, our clinical trials or regulatory approval may be ~~adequate~~delayed, or could impair our ability to ~~complete ongoing and future clinical studies.~~generate revenue from the sale of such product candidate.

We rely and expect to continue to rely on third parties to manufacture our clinical product supplies, and if those third parties fail to obtain approval of government regulators, fail to provide us with sufficient quantities of drug product, or fail to do so at acceptable quality levels or prices our product candidates could be stopped, delayed, or made less profitable.

We do not currently have nor do we plan to acquire the infrastructure or capability internally to manufacture our clinical supplies for use in the conduct of our clinical trials, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. We currently rely on outside vendors to source raw materials and manufacture our clinical supplies of our product candidates and plan to continue relying on third parties to manufacture our product candidates on a commercial scale, if approved.

The facilities used by our contract manufacturers to manufacture our product candidates ~~must~~will be ~~approved~~subject to pre-approval inspection by the FDA ~~pursuant to inspections~~ that will be conducted after we submit our marketing applications to the ~~FDA.~~FDA or comparable foreign regulatory authorities. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements, known as cGMPs, for manufacture of our product candidates. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, ~~they will~~our MAA for Zokinvy for treatment of Progeria and processing-deficient progeroid laminopathies and future applications may not be ~~able to secure and/or maintain~~approved by regulatory ~~approval for their manufacturing facilities. In addition, we~~authorities, which would significantly delay our commercialization plans and increase our costs. We have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.

We do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing of our product candidates, and the actual cost to manufacture our product candidates could materially and adversely affect the commercial viability of our product candidates. As a result, we may ~~never~~not be able to develop aadditional commercially viable ~~product.~~products.

In addition, our reliance on third-party manufacturers exposes us to the following additional risks:

Each of these risks could delay our clinical trials, the approval ifof any of our product candidates by the FDA or comparable foreign regulatory authorities or the commercialization of our product candidates or result in higher costs or deprive us of potential product revenue. In addition, we rely on third parties to perform release testing on our product candidates prior to delivery to patients. If these tests are not conducted appropriately ~~conducted~~ and test data ~~are~~is not reliable, patients could be put at risk of serious harm and could result in product liability suits.

The ~~manufacture~~manufacturing of medical products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of biologic products often encounter difficulties in production, particularly in scaling up and validating initial production and absence of contamination. These problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if contaminants are discovered in our supply of our product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any stability or other issues relating to the manufacture of our product candidates will not occur in the future. Additionally, our manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If our manufacturers were to encounter any of these difficulties, or otherwise fail to comply with their contractual obligations, our ability to provide our product candidates to patients in clinical trials would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely.

If the market opportunities for our product candidates are smaller than we believe they are, we may not meet our revenue expectations and, even assuming approval of a product candidate, our business may suffer. Because the patient populations in the market for our product candidates may be small, we must be able to successfully identify patients and acquire a significant market share to achieve profitability and growth.

We focus our product development principally on treatments for ~~orphan~~rare and ultra-rare diseases. Given the small number of patients who have the diseases that we are targeting, our eligible patient population and pricing estimates may differ significantly from the actual market addressable by our product candidate. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, patient foundations, or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. For example, for lonafarnib and peginterferon lambda, HDV is associated with hepatitis B virus infection, which is a pre-requisite for the replication of HDV. Although we believe that the data are supportive of ~~the increased severity of hepatitis in the presence of hepatitis D and hepatitis B virus co-infection compared to hepatitis B alone,~~antiviral activity against HDV, there can be no assurance that our clinical trials will successfully address this condition. Likewise, the potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business. Moreover, we expect that the sales of Zokinvy to patients with Progeria, or processing-deficient progeroid laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation, or homozygous or compound heterozygous ZMPSTE24 mutations, will have limited profits given the ultra-rare nature of these diseases.

We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are similar, more advanced, or more effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates.

The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. We are currently aware of various existing therapies that may compete with our product candidates. For example, we have competitors both in the United States and internationally, including multinational pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies. Some of the pharmaceutical and biotechnology companies we expect to compete with include Gilead Sciences, Merck, Roche, ~~Actelion/~~Holding AG, Actelion Pharmaceuticals US, Inc., Johnson ~~and~~& Johnson, Replicor, Inc., Arrowhead

Pharmaceuticals, Novartis ~~Xoma, Reata~~International AG, Zealand Pharmaceuticals, Xeris Pharmaceuticals, Rezolute, Inc., Hanmi Pharmaceutical, and ~~Arena~~Crinetics Pharmaceuticals as well as other smaller companies or biotechnology startups and large multinational pharmaceutical companies. Many of our competitors have substantially greater financial, technical, and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products as well. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of

capital for investment in these industries. Our competitors may succeed in developing, acquiring, or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we may develop, or achieve earlier patent protection, regulatory approval, product commercialization, and market penetration than we do. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors.

~~We currently~~Following the FDA approval and commercial launch of Zokinvy, we have limited marketing and sales experience. If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenue.

Although certain of our employees may have marketed, launched and sold other pharmaceutical products in the past while employed at other companies, we have nolimited recent experience selling and marketing our product candidates and we currently have noa small sales and marketing ~~or sales~~ organization. To successfully commercialize ~~any~~additional products that may result from our development programs, we will need to invest in and ~~develop~~expand these capabilities, either on our own or with others, which would be expensive, difficult and time consuming. Any failure or delay in the timely development of our internal commercialization capabilities could adversely impact the potential for success of our products.

Further, given our ~~lack of prior~~recent, limited experience in marketing and selling biopharmaceutical products, we may rely on future collaborators to commercialize our products. If collaborators do not commit sufficient resources to commercialize our future products and we are unable to develop the necessary marketing and sales capabilities on our own, we will be unable to generate sufficient product revenue to sustain or grow our business. We may be competing with companies that currently have extensive and well-funded marketing and sales operations, in particular in the markets our product candidates are intended to address. Without appropriate capabilities, whether directly or through third-party collaborators, we may be unable to compete successfully against these more established companies. In addition, we have established an expanded access program in order to make Zokinvy available for patients with Progeria and processing-deficient progeroid laminopathies, which requires additional resources and costs to support.

The commercial success of any of our current or future product ~~candidate~~candidates will depend upon the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community.

Even with the approvals from the FDA and comparable foreign regulatory authorities, the commercial success of our products will depend in part on the health care providers, patients, and third-party payors accepting our product candidates as medically useful, cost-effective, and safe. Any product that we bring to the market may not gain market acceptance by physicians, patients, third-party payors and other health care providers. The degree of market acceptance of any of our products will depend on a number of factors, including without limitation:

~~the pricing and availability of third-party insurance coverage and reimbursement.~~

Even if a product displays a favorable efficacy and safety profile upon approval, market acceptance of the product remains uncertain. Efforts to educate the medical community and third-party payors on the benefits of the products may require significant investment and resources and may never be successful. If our products fail to achieve an adequate level of acceptance by physicians, patients, third-party payors, and other health care providers, we will not be able to generate sufficient revenue to become or remain profitable.

Failure to obtain or maintain adequate reimbursement or insurance coverage for new or current products could limit our ability to market those products and decrease our ability to generate revenue.

The pricing, coverage and reimbursement of our products must be sufficient to support our commercial efforts and other development programs and the availability and adequacy of coverage and reimbursement by governmental and private payors are essential for most patients to be able to afford expensive treatments, particularly in ~~orphan drug~~Orphan Drug designated indications where the eligible patient population is small. Sales of our ~~product candidates~~products will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid for or reimbursed by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or government authorities, private health insurers, and other third-party payors. If coverage and reimbursement are not available, or are available only in limited amounts, we may have to subsidize or provide products for free or we may not be able to successfully commercialize our products. For example, Zokinvy for patients with Progeria and processing-deficient progeroid laminopathies provided under an expanded access program may not result in reimbursement.

In addition, there is significant uncertainty related to the insurance coverage and reimbursement for newly approved products. In the United States, the principal decisions about coverage and reimbursement for new drugs are typically made by the Centers for Medicare & Medicaid Services ~~or CMS,~~(CMS), an agency within the U.S. Department of Health and Human Services (HHS), as CMS decides whether and to what extent a new drug will be covered and reimbursed under Medicare. Private payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for products such as ours and what reimbursement codes our products may receive.

The process for determining whether a third-party payor will provide coverage for a drug product typically is separate from the process for setting the price of a drug product or for establishing the reimbursement rate that the payor will pay for the drug product once coverage is approved. Third-party payors may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. A decision by a third-party payor not to cover Zokinvy or any of our product candidates once approved could reduce physician utilization of such products and have a material adverse effect on our sales, results of operations and financial condition. Moreover, a third-party payor’s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Additionally, coverage and reimbursement for drug products can differ significantly from payor to payor. One third-party payor’s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service or will provide coverage at an adequate reimbursement rate. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payor separately and will be a time-consuming process.

Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost-effectiveness of drug products and medical services, in addition to questioning safety and efficacy. If these third-party payors do not consider our products to be cost-effective compared to other available therapies, they may not cover our products after FDA approval or, if they do, the level of payment may not be sufficient to allow us to sell our products at a profit. Additionally, coverage policies and third‑party reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained for one or more of our products, less favorable coverage policies and reimbursement rates may be implemented in the future. If we are unable to obtain and maintain sufficient third‑party coverage and adequate reimbursement, the commercial success of our products may be greatly hindered and our financial condition and results of operations may be materially and adversely affected.

Outside the United States, international operations are generally subject to extensive governmental price controls and other price-restrictive regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, and other countries has and will continue to put pressure on the pricing and usage of products. In many countries, the prices of products are subject to varying price control mechanisms as part of national health systems. Price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products. Accordingly, in markets outside the United States, the potential revenue may be insufficient to generate commercially reasonable revenue and profits.

Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to limit or reduce healthcare costs may result in restrictions on coverage and the level of reimbursement for new products and, as a result, they may not cover or provide adequate payment for our products. We expect to experience pricing pressures in connection with products due to the increasing trend toward managed healthcare, including the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs, has and is expected to continue to increase in the future. As a result, profitability of our products may be more difficult to achieve even if they receive regulatory approval.

We intend to rely on a combination of exclusivity from ~~orphan drug~~Orphan Drug designation as well as patent rights for our product candidates and any future product candidates. If we are unable to obtain or maintain exclusivity from the combination of these approaches, we may not be able to compete effectively in our markets.

Our business strategy is to focus on product candidates for which ~~orphan drug~~Orphan Drug designation may be obtained in the major markets of the world. In addition, we rely or will rely upon a combination of patents, trade secret protection, and confidentiality agreements to protect the intellectual property related to our technologies and product candidates. For example, the portfolio of patents licensed from Merck expires before the anticipated launch date of ~~the lonafarnib product candidate.~~lonafarnib. Our success depends in large part on our and our licensors’ ability to obtain regulatory exclusivity and maintain patent and other intellectual property protection in the United States and in other countries with respect to our proprietary technology and products.

Under the Orphan Drug Act, the FDA may designate a product as an ~~orphan drug~~Orphan Drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the European Union (the EU), the EMA’s Committee for Orphan Medicinal Products ~~or COMP,~~(COMP) grants ~~orphan drug~~Orphan Drug designation to promote the development of products that are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the ~~European Union.~~EU. Additionally, designation is granted for products intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the ~~European Union~~EU would be sufficient to justify the necessary investment in developing the drug or biological product or where there is no satisfactory method of diagnosis, prevention, or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition.

In the United States, ~~orphan drug~~Orphan Drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has ~~orphan drug~~Orphan Drug designation, the product is entitled to ~~orphan drug~~Orphan Drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity. In the ~~European Union, orphan drug~~EU, Orphan Drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval. This period may be reduced to six years if the ~~orphan drug~~Orphan Drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.

Because the extent and scope of patent protection for our products may in some cases be limited, ~~orphan drug~~Orphan Drug designation is especially important for our products for which ~~orphan drug~~Orphan Drug designation may be available. For eligible drugs, we plan to rely on the exclusivity period under the Orphan Drug Act to maintain a competitive position. If we do not obtain ~~orphan drug~~Orphan Drug exclusivity for our drug products and biologic products that do not have broad patent protection, our competitors may then sell the same drug to treat the same condition sooner than if we had obtained ~~orphan drug~~Orphan Drug exclusivity and our revenue will be reduced.

Even though we have ~~orphan drug designation~~Orphan Drug designations for ~~lonafarnib~~each of our development programs in the United States and Europe, we may not be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. Further, even if we obtain ~~orphan drug~~Orphan Drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties can be approved for the same condition. Even after an ~~orphan drug~~Orphan Drug is approved, the FDA or EMA can subsequently approve the same drug with the same active moiety for the same condition if the FDA or EMA concludes that the later drug is safer, more effective, or makes a major contribution to patient care. Orphan ~~drug~~Drug designation neither shortens the development time or regulatory review time of a product candidate nor gives the product candidate any advantage in the regulatory review or approval process.

We have sought to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates that are important to our business. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.

The patent position of biotechnology and pharmaceutical companies generally is highly uncertain and involves complex legal and factual questions for which legal principles remain unsolved. The patent applications that we own or ~~in-licenses~~in-licensed may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our product candidates, third parties may challenge their validity, enforceability, or scope, which may result in such patents being narrowed, found unenforceable or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates, or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.

We, independently or together with our licensors, have filed several patent applications covering various aspects of our product candidates. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or licensed to us after patent issuance could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.

Although we have licensed a number of patents covering methods of use and certain compositions of matter, we do not have complete patent protection for our product candidates. For example, the patent coverage for the lonafarnib composition of matter expires before the anticipated launch date. Likewise, most of the patents or applications covering products that we have licensed in from Stanford have limited protection outside of the United States. Therefore, a competitor could develop the same or similar product that may compete with our product candidate.

Certain of our product licenses are limited to specified indications or therapeutic areas which may result in the same compound being developed and commercialized by a third party whom we have no control over or rights against. This may result in safety data, pricing or off label uses from that third party’s product that may negatively affect the development and commercialization of our product candidates. For example, Kura has an exclusive license to tipifarnib for use in cancer indications while we have a license for anti-viral indications. As a result of Kura’s right to use the same compound in a different indication, it is possible that development and sales may impact our product development and commercialization efforts. If we cannot obtain and maintain effective protection of exclusivity from our regulatory efforts and intellectual property rights, including patent protection, for our product candidates, we may not be able to compete effectively, and our business and results of operations would be harmed.

We may not have sufficient patent term protections for our products to effectively protect our business.

Patents have a limited term. In the United States, the statutory expiration of a patent is generally 20 years after it is filed. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from generic medications. In addition, upon issuance in the United States any patent term can be adjusted based on certain delays caused by the applicant(s) or the United States Patent and Trademark Office ~~or USPTO.~~(USPTO). For example, a patent term can be reduced based on certain delays caused by the patent applicant during patent prosecution.

Patent term extensions under the Hatch-Waxman Act in the United States and under supplementary protection certificates in Europe may be available to extend the patent or data exclusivity terms of products. With respect to ~~ubenimex,~~ lonafarnib, peginterferon lambda and ~~exendin 9-39,~~avexitide, a substantial portion of the potential commercial opportunity will likely rely on patent term extensions, and we cannot provide any assurances that any such patent term extensions will be obtained and, if so, for how long. As a result, we may not be able to maintain exclusivity for our products for an extended period after regulatory approval, which would negatively impact our business and results of operations. If we do not have sufficient patent terms or regulatory exclusivity to protect our products, our business and results of operations will be adversely affected.

Patent laws and rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.

Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. We therefore cannot be certain that it or our licensors were the first to make the invention claimed in our owned and licensed patents or pending applications, or that we or our licensor were the first to file for patent protection of such inventions. Assuming the other requirements for patentability are met, in the United States prior to March 15, 2013, the first to make the claimed invention is entitled to the patent, while outside the United States, the first to file a patent application is entitled to the patent. After March 15, 2013, under the Leahy-Smith America Invents Act ~~or the~~(the Leahy-Smith ~~Act,~~Act) enacted on September 16, 2011, the United States has moved to a first to file system. The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and may also affect patent litigation. The effects of these changes are currently unclear as the USPTO must still implement various regulations, the courts have yet to address any of these provisions and the applicability of the act and new regulations on specific patents discussed herein have not been determined and would need to be reviewed. In general, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.

If we are unable to maintain effective proprietary rights for our product candidates or any future product candidates, we may not be able to compete effectively in our markets.

In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.

Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors, and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret.

Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.

Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There have been many lawsuits and other proceedings involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, and reexamination proceedings before the USPTO and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.

Third parties may assert that we are ~~employing~~using or exploiting their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture, or methods for treatment related to the use or manufacture of our product candidates. ~~We have conducted~~Even if we conduct freedom to operate analyses, we would expect to do so only with respect to ~~only~~ certain of our product candidates ~~and therefore we do not know whether~~as they move through development. Accordingly, there ~~are any~~may be third-party patents that would impair our ability to commercialize ~~these~~ product ~~candidates. We also~~candidates and we cannot ~~guarantee that any of our analyses are complete and thorough, nor can we be sure~~assure you that we ~~have identified each and every patent and pending application~~could obtain a license, or even if available, whether such license might be obtained on commercially reasonable terms. Even in ~~the United States and abroad~~those situations where we conduct a freedom to operate analysis, there can be no assurance that iswe would identify all relevant or necessary patents and patent applications that may apply to the manufacture and commercialization of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may ~~infringe.~~infringe, and if patents issue with respect to any such application and we become aware of such issuance, we would have to determine its impact on our efforts to develop and commercialize our product candidates and the strategy for obtaining a license or contesting any such issued patent.

~~In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents.~~ If any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, the manufacturing process of any of our product candidates, methods of use, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Such a license may not be available on commercially reasonable terms, or at all.

~~Parties~~If we fail to obtain a license, then parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.

We may not be successful in meeting our diligence obligations under our existing license agreements necessary to maintain our product candidate licenses in effect. In addition, if required in order to commercialize our product candidates, we may be unsuccessful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.

We currently have rights to the intellectual property, through licenses from third parties and under patents that we do not own, to develop and commercialize our product candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to maintain in effect these proprietary rights. For example, we have certain specified diligence obligations under our Stanford license ~~agreements~~agreement for ~~our ubenimex and lonafarnib product candidates.~~lonafarnib. We may not be able to achieve the required diligence milestones in a timely manner, which may result in aStanford’s right ~~of termination by Stanford,~~to terminate the license agreement, and we may be unable to successfully negotiate an extension or waiver of those termination rights. Any termination of license agreements with third parties with respect to our product candidates would be expected to negatively impact our business prospects.

We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Even if we are able to license or acquire third-party intellectual property rights that are necessary for our product candidates, there can be no assurance that they will be available on favorable terms.

We collaborate with U.S. and foreign academic institutions to identify product candidates, accelerate our research and conduct development. Typically, these institutions have provided us with an option to negotiate an exclusive license to any of the institution’s rights in the patents or other intellectual property resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue a program of interest to us.

If we are unable to successfully obtain and maintain rights to required third-party intellectual property, we may have to abandon development of that product candidate or pay additional amounts to the third party, and our business and financial condition could suffer.

Our product candidates marketed under an NDA may be subject to generic competition.

Under the Hatch-Waxman Act, a pharmaceutical manufacturer may file an abbreviated new drug application ~~or ANDA,~~(ANDA) seeking approval of a generic copy of an approved innovator product marketed under an NDA. Generally, in place of clinical studies intended to demonstrate safety or effectiveness, an ANDA applicant usually needs only to submit data demonstrating that its product has the same active ingredient(s), strength, dosage form, route of administration and that it is bioequivalent to the branded product. Under the Hatch-Waxman Act, a manufacturer may also submit an NDA under section 505(b)(2) that references the FDA’s finding of safety and effectiveness of a previously approved drug. A 505(b)(2) NDA product may be for a new or improved version of the original innovator product.

Innovative small molecule drugs may be eligible for certain periods of regulatory exclusivity (e.g., five years for new chemical entities, three years for changes to an approved drug requiring a new clinical study, seven years for ~~orphan drugs)~~Orphan Drugs), which preclude FDA approval (or in some circumstances, FDA filing and review of) an ANDA or 505(b)(2) NDA relying on the FDA’s finding of safety and effectiveness for the innovative drug. In addition to the benefits of regulatory exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product formulation or an approved use of the drug, which would be listed with the product in the FDA publication, “Approved Drug Products with Therapeutic Equivalence Evaluations,” known as the “Orange Book.” If there are patents listed in the Orange Book, a generic applicant that seeks to market its product before expiration of the patents must include in the ANDA or 505(b)(2) what is known as a “Paragraph IV certification,” challenging the validity or enforceability of, or claiming non-infringement of, the listed patent or patents. Notice of the certification must be given to the innovator, too, and if within 45 days of receiving notice the innovator sues to protect its patents, approval of the ANDA is stayed for 30 months, or as lengthened or shortened by the court.

If there are patents listed for our ~~product candidates~~products in the Orange Book after approval by FDA, ANDAs and 505(b)(2) NDAs with respect to those ~~product candidates~~products would be required to include a certification as to each listed patent indicating whether the ANDA applicant does or does not intend to challenge the patent. We cannot predict whether any patents issuing from our pending patent applications will be eligible for listing in the Orange Book, how any generic competitor would address such patents, whether we would sue on any such patents, or the outcome of any such suit.

We may not be successful in securing or maintaining proprietary patent protection in the United States and/or in other countries for products and technologies we develop or license. Moreover, if any patents that are granted and listed in the Orange Book are successfully challenged by way of a Paragraph IV certification and subsequent litigation, the affected product could more immediately face generic competition and its sales would likely decline materially. Should sales decline, we may have to write off a portion or all of the intangible assets associated with the affected product and our results of operations and cash flows could be materially and adversely affected.

The patent protection and patent prosecution for some of our product candidates is dependent on third parties.

While we normally seek and gain the right to fully prosecute the patents relating to our product candidates, there may be times when patents relating to our product candidates are controlled by our licensors. This is the case with our agreements with Stanford and Nippon Kayaku, each of whom is primarily responsible for the prosecution of patents and patent applications licensed to us under the applicable collaboration agreements. If they or any of our future licensors fail to appropriately and broadly prosecute and maintain patent protection for patents covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using, importing, and selling competing products. In addition, even where we now have the right to control patent prosecution of patents and patent applications, we have licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensors in effect from actions prior to us assuming control over patent prosecution.

If we fail to comply with obligations in the agreements under which we license intellectual property and other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.

We are a party to a number of intellectual property license and supply agreements that are important to our business and expects to enter into additional license agreements in the future. Our existing agreements impose, and we expect that future license agreements will impose, various diligence, milestone payment, royalty, purchasing, supply and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, our agreements may be subject to termination by the licensor, in which event we would not be able to develop, manufacture or market products covered by the license or subject to supply commitments.

Although we are not currently involved in any intellectual property litigation, we may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful.

Competitors may infringe our patents or the patents of our licensors. Although we are not currently involved in any intellectual property litigation, if we or one of our licensing partners were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable.

Interference proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.

We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we have written agreements and make every effort to ensure that our employees, consultants and independent contractors do not use the proprietary information or intellectual property rights of others in their work forums, and we are not currently subject to any claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties, we may in the future be subject to such claims. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

We may not be able to protect our intellectual property rights throughout the world.

Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. Likewise, certain of our license agreements, for example for ubenimex, do not include patents or patent applications outside of the United States as our licensor elected not to file in foreign jurisdictions. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

We have previously identified a material weakness in our internal control over financial reporting and our current management team may fail to maintain an effective system of internal control, which may result in material misstatements of our financial statements or cause us to fail to meet our periodic reporting obligations as a public company.

In connection with the audit of our consolidated financial statements for the years ended December 31, 2015 and 2014 as a private company, we and our independent auditors identified a material weakness in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the subject company’s annual or interim financial statements will not be prevented or detected on a timely basis. Our lack of sufficient accounting personnel resulted in the identification of a material weakness in our internal control over financial reporting. Specifically, the material weakness that was identified related to a lack of sufficient accounting resources and personnel that had limited our ability to adequately segregate duties, perform sufficient review and approval of manual journal entries posted to the general ledger, establish defined accounting policies and procedures or perform timely reviews of account reconciliations or accounting estimates.

During 2016, we implemented measures to improve our internal control over financing reporting to address the underlying causes of the previously identified material weakness, including (i) the hiring of our Controller and other accounting personnel, (ii) establishing segregation of duties for review and approval of manual journal entries, (iii) establishing accounting policies and procedures, (iv) performing timely reviews of account reconciliations and accounting estimates, and (v) implementing appropriate disclosure controls and procedures. We believe the remediation steps outlined above were sufficient to remediate the previously identified material weakness in internal control over financial reporting as discussed above.

Our failure to implement and maintain effective internal control over financial reporting could result in errors in our financial statements that could result in a restatement of our financial statements or cause us to fail to meet our reporting obligations. In addition, although we are not currently required to formally test our internal controls for attestation, we are required as an “emerging growth company” to report on our internal controls. After we are no longer an emerging growth company, any testing by us conducted in connection with Section 404 of the Sarbanes-Oxley Act, or the subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our consolidated financial statements or identify other areas for further attention or improvement. Inadequate internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock.

Our future success depends in part on our ability to retain our President and Chief Executive Officer and to attract, retain, and motivate other qualified personnel.

We are highly dependent on David Cory, our President and Chief Executive Officer, the loss of whose services may adversely impact the achievement of our objectives. Mr. Cory could leave our employment at any time, as he is an “at will” employee. Recruiting and retaining other qualified employees, consultants, and advisors for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of highly qualified personnel in our industry, which is likely to continue. As a result, competition for personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for individuals with similar skill sets. In addition, failure to succeed in development and commercialization of our product candidates may make it more challenging to recruit and retain qualified personnel. The inability to recruit and retain qualified personnel, or the loss of the services of Mr. Cory, may impede the progress of our research, development, and commercialization objectives and would negatively impact our ability to succeed in our in-licensing strategy.

We will need to expand our organization and we may experience difficulties in managing this growth, which could disrupt our operations.*

As of September 30, ~~2017,~~2021, we had 1734 full-time employees. As our development and commercialization plans and strategies develop, we expect to need additional managerial, operational, manufacturing, sales, marketing, financial, legal, and other resources. Our management may need to divert a disproportionate amount of their attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees, and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.

Failure to comply with existing or future laws and regulations related to privacy or data security could lead to government enforcement actions (which could include civil or criminal fines or penalties), private litigation, other liabilities, and/or adverse publicity. Compliance or the failure to comply with such laws could increase the costs of our products and services, could limit their use or adoption, and could otherwise negatively affect our operating results and business.

Regulation of data processing is evolving as federal, state, and foreign governments continue to adopt new, or modify existing, laws and regulations addressing data privacy and security, and the collection, processing, storage, transfer, and use of data. We and our partners may be subject to current, new, or modified federal, state, and foreign data protection laws and regulations (e.g., laws and regulations that address data privacy and data security including, without limitation, health data). These new or proposed laws and regulations are subject to differing interpretations and may be inconsistent among jurisdictions, and guidance on implementation and compliance practices are often updated or otherwise revised, which adds to the complexity of processing personal data. These and other requirements could require us or our partners to incur additional costs to achieve compliance, limit our competitiveness, necessitate the acceptance of more onerous obligations in our contracts, restrict our ability to use, store, transfer, and process data, impact our or our partners’ ability to process or use data in order to support the provision of our products or services, affect our or our partners’ ability to offer our products and services in certain locations, or cause regulators to reject, limit or disrupt our clinical trial activities.

In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act) that govern the collection, use, disclosure, and protection of health-related and other personal information apply to our operations or the operations of our partners. In addition, we may receive unintended health information in error from third parties (including research institutions from which we may obtain clinical trial data) that are subject to privacy and security requirements under the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH). Depending on the facts and circumstances, we could be subject to significant penalties if we obtain, use, or disclose individually identifiable health information in a manner that is not authorized or permitted by HIPAA.

In particular, several state laws have recently been passed or amended to significantly expand privacy rights and obligations of businesses that process personal information, including identifiable sensitive health information. For example, in June 2018, California enacted the California Consumer Privacy Act (CCPA), which went into effect on January 1, 2020. The CCPA gives

California residents expanded rights to access and require deletion of their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that may increase data breach litigation. The CCPA was amended by referendum that passed in November of 2020, which will expand California privacy rights and obligations substantially on January 1, 2023 when the California Privacy Rights Act of 2020 (“CPRA”) becomes fully operative. The CPRA will, among other things, give consumers the ability to limit use of information deemed to be sensitive, increase the maximum penalties for violations concerning consumers under age 16, and establish the California Privacy Protection Agency to implement and enforce the new law and impose administrative fines. Following the CPRA, Virginia and Colorado have enacted similar, but not completely consistent, comprehensive privacy legislation that will also go into effect in January and July 2023, respectively. Many other states are considering similar legislation.

Aspects of the these new state privacy laws, and their interpretation and enforcement, remain uncertain. The potential effects of these new and evolving state privacy laws are far-reaching and may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply. Although the California, Virginia and Colorado laws include exemptions for certain clinical trials data and HIPAA protected health information, the law may increase our compliance costs and potential liability with respect to other personal information we collect about California residents, and those health-data related exceptions may evolve through amendment or regulatory interpretation. The state privacy law developments, moreover, have prompted a number of additional proposals for new federal and state privacy legislation that, if passed, could increase our potential liability, increase our compliance costs and adversely affect our business.

Foreign data protection laws, including, without limitation, the EU General Data Protection Regulation (EU GDPR) that took effect in May 2018, and EU Member State data protection legislation, may also apply to health-related and other personal information obtained from individuals. The EU GDPR has direct effect in all EU Member States and has extraterritorial effect where organizations outside of the EU process personal information of individuals in the EU in relation to the offering of goods or services to those individuals (“targeting test”) or the monitoring of their behavior (“monitoring test”). As such, the EU GDPR applies to us to the extent we are established in an EU Member State or we meet the requirements of either the targeting test or the monitoring test. These laws impose strict obligations on businesses, including: (i) accountability and transparency requirements, including enhanced requirements for obtaining informed and valid consent and the provision of more detailed privacy notices for clinical trial subjects and investigators; (ii) obligations to consider data protection as any new products or services are developed and limitations on the amount of personal information processed; (iii) establishing a legal basis for processing personal information; (iv) obligations to implement appropriate technical and organizational measures to safeguard personal information and to notify security incidents to appropriate data protection authorities without undue delay (and no later than 72 hours where feasible) and/or concerned data subjects; and (v) establishing means for data subjects to exercise rights in relation to their personal information (e.g., the right to erasure of personal information).

The EU GDPR restricts the transfer of personal information from the European Economic Area (EEA) to the United States and other countries that the European Commission does not recognize as having “adequate” data protection laws unless the parties to the transfer have implemented an appropriate data transfer mechanism in accordance with the EU GDPR. Data protection laws in the United Kingdom (as discussed below) and Switzerland impose similar restrictions. One of the primary mechanisms allowing United States companies to import personal information from Europe had been certification to the EU-U.S. Privacy Shield and Swiss-U.S. Privacy Shield frameworks administered by the United States Department of Commerce. However, in July 2020, the Court of Justice of the EU (CJEU) invalidated the EU-U.S. Privacy Shield, and subsequent regulatory guidance required additional compliance efforts to analyze international data flows and take steps to ensure adequate protections for personal data transferred to the United States and other certain jurisdictions, including by implementing supplementary measures that provide privacy protections in addition to those provided under the Standard Contractual Clauses (or SCCs). Moreover, new versions of the European Commission’s Standard Contractual Clauses, now the primary mechanism for the lawful transfer of personal information transfers from Europe to the United States or other countries, have been released requiring additional compliance and implementation efforts. Similarly, the Swiss Federal Data Protection and Information Commissioner announced that the Swiss-U.S. Privacy Shield Framework is inadequate for personal information transfers from Switzerland to the United States in light of the CJEU’s July 2020 decision, and also raised questions about the viability of the older version of the Standard Contractual Clauses. As such, any transfers by us or our vendors of personal information from Europe may not comply with European data protection law, may increase our exposure to the EU GDPR’s heightened sanctions for violations of its cross-border data transfer restrictions and may reduce demand from companies subject to European data protection laws. Moreover, where we rely on SCCs, we must now evaluate and implement supplementary measures that provide privacy protections additional to those provided under SCCs. This evaluation will, in particular, include an assessment as to whether the types of personal data transferred pursuant to SCCs may be subject to government surveillance in the data importer’s country and an assessment as to whether the data importer can meet its contractual obligations under the SCCs. Although we rely primarily on individuals’ explicit consent to transfer their personal information from Europe to the United States and other countries, in certain cases we have relied or may rely on the Standard Contractual Clauses. If we are unable to rely on explicit consent to transfer individuals’ personal information from Europe, which can be revoked, or are required to implement another valid data transfer solution, we will face increased exposure to substantial fines under European data protection laws as well as injunctions against

processing personal information from Europe. Inability to import personal information from the European Economic Area, United Kingdom or Switzerland may also restrict our clinical trial activities in Europe; limit our ability to collaborate with CROs, service providers, contractors and other companies subject to European data protection laws; and require us to increase our data processing capabilities in Europe at significant expense.

Further, following a referendum in June 2016 in which voters in the United Kingdom approved an exit from the EU, the United Kingdom government initiated a process to leave the EU, known as Brexit. Following December 31, 2020, the EU GDPR’s data protection obligations continue to apply to the United Kingdom in substantially unvaried form under the so called “UK GDPR” by virtue of section 3 of the European Union (Withdrawal) Act 2018. Under the UK GDPR, companies not established in the United Kingdom but who process personal data in relation to the offering of goods or services to individuals in the United Kingdom, or to monitor their behavior will be subject to the UK GDPR – the requirements of which are (at this time) largely aligned with those under the EU GDPR and as such, may lead to similar compliance and operational costs with potential fines of up to £17.5 million or 4% of global turnover.

Additionally, other countries outside of Europe continue to enact or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business. For example, Brazil enacted the General Data Protection Law (Lei Geral de Proteção de Dados Pessoais or LGPD) (Law No. 13,709/2018), which broadly regulates the processing of personal information and imposes compliance obligations and penalties comparable to those of the EU GDPR.

Under the EU GDPR, regulators may impose substantial fines and penalties for non-compliance. Companies that violate the EU GDPR can face fines of up to the greater of 20 million Euros or 4% of their consolidated worldwide annual turnover (revenue) and restrictions or prohibitions on data processing. The EU also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the EU GDPR. The EU GDPR has increased our responsibility and liability in relation to personal information that we process, requiring us to put in place additional mechanisms to ensure compliance with the EU GDPR and other EU and international data protection rules. There may also be a risk that the measures will not be implemented correctly or that individuals within the business will not be fully compliant with the required procedures.

Failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties, fines or sanctions), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, patients about whom we or our partners obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals’ privacy rights, failed to comply with data protection laws, or breached our contractual obligations related to security or privacy, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. Compliance with data protection laws may be time-consuming, require additional resources and could result in increased expenses, reduce overall demand for our products and services and make it more difficult to meet expectations of or commitments to customers or partners.

Any of these matters could materially adversely affect our business, financial condition, or operational results.

Failure in our information technology and storage systems or our security measures, including without limitation, data breaches, or inadequacy of our business continuity and disaster recovery plans and procedures, could significantly disrupt the operation of our business.

Our ability to execute our business plan and maintain operations depends on the continued and uninterrupted performance of our, and our third-party vendors’, information technology or(IT) systems, and the availability of data related to our products, services and operations. IT ~~systems. IT~~ systems and data are vulnerable to risks and damages from a variety of sources, including catastrophe or natural disaster, telecommunications or network failures, malicious human acts, ~~and~~breaches of security, cyber-attacks, loss of power or other natural ~~disasters.~~or man-made events. Moreover, despite network security and back-up measures, ~~some of~~we and our vendors frequently defend against and respond to data security attacks and incidents, and our, and =our and our vendors’ servers are potentially vulnerable to physical or electronic break-ins, computer viruses, software vulnerabilities, ransomware attacks and similar disruptive problems. If our business continuity and disaster recovery plans and procedures were disrupted, inadequate or unsuccessful in the event of a problem, we could experience a material adverse interruption of our operations.

Specifically, data security breaches, whether inadvertent or intentional, by employees or others, may expose proprietary information, trade secrets, personal information, clinical trial data or other sensitive data to unauthorized persons, impact the integrity, availability or confidentiality of our IT systems or data (including, but not limited to, data loss), or disrupt or interrupt our IT systems or operations. Our partners and vendors face similar risks and any security breach of their systems could adversely affect our security

posture. Malicious attacks by third parties are of ever-increasing sophistication and can be made by groups and individuals with a wide range of motives (including, but not limited to, industrial espionage and financial motivation prompted by the enormous growth in ransomware over the past several years) and expertise, including organized criminal groups, “hacktivists,” nation states and others. Foreign, federal, and state laws or regulations allows for the imposition of civil liability, fines and/or corrective action on entities that improperly use or disclose the personal information of individuals, including through a data security breach. Accordingly, data security breaches experienced by us, our collaborators or contractors could lead to significant fines, required corrective action, loss of trade secrets or other intellectual property, or could lead to the public exposure of personally identifiable information (including sensitive personal information) of our employees, collaborators, clinical trial patients, and others. A data security breach or privacy violation that leads to disclosure or modification of or prevents access to personal information, including personally identifiable information, patient information or protected health information, could result in civil liability, harm our reputation, compel us to comply with federal and/or state breach notification laws, subject us to mandatory corrective action, require us to verify the correctness of database contents and otherwise subject us to liability under laws and regulations that protect personal data, resulting in increased costs or loss of revenue. If we are unable to adequately prevent, detect or respond to data security breaches or privacy violations, or implement satisfactory remedial measures in the wake of a data security incident, our operations could be disrupted, and we may suffer civil liability to our customers or individuals, loss of reputation, financial loss and other regulatory penalties because of lost or misappropriated information, including sensitive patient data, or our clinical trials may be adversely impacted from data loss resulting in delayed regulatory approvals or other operational impacts. In addition, these breaches and other inappropriate access events can be difficult to detect, and any delay in identifying and responding to them may lead to increased harm of the type described above. Moreover, the prevalent use of mobile devices or other remote working activity that access and process confidential information remotely increases the risk of data security breaches, which could lead to the loss of confidential information, trade secrets or other intellectual property. While we have implemented security measures designed to protect our data security and information technology systems, no set of security measures is infallible, and these measures may not prevent such events.

For example, in March 2021, we learned we were the victim of a business email compromise during which an unauthorized party gained access to the email account of an employee in our finance department. It is estimated that the incident will result in a loss of approximately $0.3 million. We immediately notified law enforcement and relevant banks involved in the wire, which we are working to recover. At this time, we do not know if we will be able to recover this loss, which we understand was transferred to another country. Based on our investigation to date, the incident was financially motivated and impacted a single email account. In response to the incident, we conducted a review of our corporate information technology and email policies and are implementing additional security measures.

Despite precautionary measures to prevent anticipated and unanticipated problems, including data breaches, there can be no assurance that our efforts to protect our data and information technology systems will prevent breakdowns or breaches in our systems (or that of our third-party providers). Such events could affect our IT systems, sustained or repeated system failures that interrupt our ability to generate, use and maintain data or our IT systems could adversely affect our ability to operate our ~~business.~~business and result in increased costs or loss of revenue, other financial and reputational harm to us, theft of trade secrets and other proprietary information, legal claims or proceedings, liability under laws that protect the privacy of personal information and regulatory penalties.

The financial exposure from the events referenced above could either not be insured against or not be fully covered through any insurance that we maintain. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages as a result of the events referenced above.

We may not be successful in any efforts to identify, license, discover, develop or commercialize additional product candidates.

Although a substantial amount of our effort will focus on the continued clinical testing, potential approval, and commercialization of our existing product candidates, the success of our business is also expected to depend in part upon our ability to identify, license, discover, develop, or commercialize additional product candidates. Research programs to identify new product candidates require substantial technical, financial, and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. Our research programs or licensing efforts may fail to yield additional product candidates for clinical development and commercialization for a number of reasons, including but not limited to the following:

If any of these events occur, we may be forced to abandon our development efforts for a program or programs, or we may not be able to identify, license, discover, develop, or commercialize additional product candidates, which would have a material adverse effect on our business and could potentially cause us to cease operations.

Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.*

In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act ~~or the ACA,~~(ACA) was passed, which substantially ~~changes~~changed the way health care is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. ~~Some of the provisions of the Affordable Care Act~~There have ~~yet to be fully implemented, and since its enactment, there have~~ been executive, judicial and Congressional challenges to numerous provisions of the ~~ACA, as well as recent efforts by the Trump administration to~~ACA. While Congress has not passed comprehensive repeal ~~or replace certain aspects of the ACA. Since January 2017, President Trump~~legislation, it has ~~signed two Executive Orders designed to delay the implementation of any~~enacted laws that modify certain provisions of the ACA ~~or otherwise circumvent some~~such as removing penalties, starting January 1, 2019, for not complying with the ACA’s individual mandate to carry health insurance and delaying the implementation of certain ACA-mandated fees. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated “Cadillac” tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress as part of the ~~requirements for health insurance mandated by~~Tax Cuts and Jobs Act of 2017. Additionally, on December 18, 2019, the ~~ACA. The Trump administration has also announced that it will discontinue the payment~~U.S. Court of ~~cost-sharing reduction, or CSR, payments to insurance companies until Congress approves the appropriation of funds~~Appeals for the ~~CSR payments. The loss~~5th Circuit upheld the District Court ruling that that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ~~CSR payments~~ACA are invalid as well. The U.S. Supreme Court is ~~expected to increase premiums on certain policies issued by qualified health plans under~~currently reviewing this case, although it is unclear when a decision will be made. On February 10, 2021, the ~~ACA.~~ ~~A bipartisan bill to appropriate funds~~Biden administration withdrew the federal government’s support for ~~CSR payments has been introduced in the Senate, but the future of that bill is uncertain.~~ ~~Further, each chamber of Congress has put forth multiple bills designed to repeal or repeal and replace portions of~~overturning the ACA. Although ~~none~~the U.S. Supreme Court has not yet ruled on the constitutionality of the ACA, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began on February 15, 2021 and will remain open through August 15, 2021. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how the U.S. Supreme Court ruling, other such litigation, and the healthcare reform measures of the Biden administration will impact the ACA and our business.

Also, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products For example, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to drug pricing that seeks to implement several of the administration’s proposals. As a result, the FDA released a final rule on September 24, 2020, effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed until January 1, 2023. On November 20, 2020, CMS issued an interim final rule implementing President Trump’s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. It is unclear whether the Biden administration will work to reverse these measures ~~has been enacted by Congress~~or pursue similar policy initiatives. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to ~~date, Congress may consider~~control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other ~~legislation to repeal~~countries and ~~replace elements of the ACA.~~ bulk purchasing. Any repeal and replace legislation may have the effect of

limiting the amounts that government agencies will pay for healthcare products and services. Policy changes, including potential modification or repeal of all or parts of the ~~Affordable Care Act~~ACA or the implementation of new health care legislation, could result in significant changes to the health care system, which may prevent us from being able to generate revenue, attain profitability or

commercialize our drugs. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand or lower pricing for our product candidates, or additional pricing pressures.

In the United States, the ~~European Union~~EU and other potentially significant markets for our product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which has resulted in lower average selling prices. For example, in the United States, there have been several recent Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. Furthermore, the increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in the ~~European Union~~EU will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic.

We may be subject, directly or indirectly, to foreign, federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If we are unable to comply, or ~~has~~have not fully complied, with such laws, itwe could face substantial ~~penalties.~~penalties, sanctions or other liability.

~~If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our~~Our operations may be subject to various foreign, federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act, ~~and~~ physician sunshine laws, the EU GDPR and other regulations. These laws may impact, among other things, our ~~proposed~~research, sales, marketing, and education programs. In addition, we may be subject to patient privacy regulation by ~~both the~~foreign, federal, ~~government~~ and ~~the states~~state governments in which we conduct our business. The laws that may affect our ability to operate include:

Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened these laws.

If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply, we may be subject to penalties, including significant civil, criminal and ~~criminal~~administrative penalties, damages, disgorgement, fines, sanctions, exclusion from participation in government health care programs, such as Medicare and Medicaid, imprisonment, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

The withdrawal of the United Kingdom from the EU, commonly referred to as “Brexit,” may adversely impact our ability to obtain regulatory approvals of our product candidates in the EU, result in restrictions or imposition of taxes and duties for importing our product candidates into the EU, and may require us to incur additional expenses in order to develop, manufacture and commercialize our product candidates in the EU.

On June 23, 2016, the U.K. held a referendum in which a majority of the eligible members of the electorate voted for the U.K. to leave the EU. The U.K’s withdrawal from the EU is commonly referred to as Brexit. The U.K. and the EU agreed to a withdrawal agreement (the Withdrawal Agreement) pursuant to which the U.K. formally left the EU on January 31, 2020. Under the Withdrawal Agreement, the U.K. is subject to a transition period until December 31, 2020 (the Transition Period), during which EU rules will continue to apply. Due to the current COVID-19 global pandemic, negotiations between the U.K. and the EU scheduled for March are either being postponed or occurring in a reduced forum via video conference. There is, therefore, an increased likelihood that the Transition Period may need to be extended beyond December 31, 2020 (although it remains the position of the U.K. government that it will not be extended).

Since a significant proportion of the regulatory framework in the U.K. applicable to our business and our product candidates is derived from EU directives and regulations, Brexit, following the Transition Period, could materially impact the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates in the U.K. or the EU. For example, as a result of the uncertainty surrounding Brexit, the European Medicines Agency (EMA) relocated to Amsterdam from London. Following the Transition Period, the U.K. will no longer be covered by the centralized procedures for obtaining EU-wide marketing authorization from the EMA and, unless a specific agreement is entered into, a separate process for authorization of drug products, including our product candidates, will be required in the U.K., the potential process for which is currently unclear. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the U.K. or the EU and restrict our ability to generate revenue and achieve and sustain profitability. In addition, we may be required to pay taxes or duties or be subjected to other hurdles in connection with the importation of our product candidates into the EU, or we may incur expenses in establishing a manufacturing facility in the EU in order to circumvent such hurdles. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the U.K. or the EU for our product candidates, or incur significant additional expenses to operate our business, which could significantly and materially harm or delay our ability to generate revenues or achieve profitability of our business. Any further changes in international trade, tariff and import/export regulations as a result of Brexit or otherwise may impose unexpected duty costs or other non-tariff barriers on us. These developments, or the perception that any of them could occur, may significantly reduce global trade and, in particular, trade between the impacted nations and the U.K. It is also possible that Brexit may negatively affect our ability to attract and retain employees, particularly those from the EU.

Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.

We are exposed to the risk of fraudulent conduct or other illegal activity by our employees, independent contractors, principal investigators, consultants, commercial partners and vendors. Misconduct by these parties could include intentional, reckless and/or negligent conduct that fails to: comply with the regulations of the FDA and non-U.S. regulators, provide accurate information to the FDA and non-U.S. regulators, comply with healthcare fraud and abuse laws in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, promotion, sales, marketing and certain business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of patient recruitment or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of business conduct and ethics applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.

We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use or misuse of our product candidates harm patients or is perceived to harm patients even when such harm is unrelated to our product candidates, our regulatory approvals could be revoked or otherwise negatively impacted, and we could be subject to costly and damaging product liability claims.

The use or misuse of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:

We believe our current product liability insurance coverage is appropriate in light of our clinical programs; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for product candidates, we intend to increase our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability ~~claim~~claims or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.

Patients with the diseases targeted by our product candidates are often already in severe and advanced stages of disease and have both known and unknown significant pre-existing and potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may or may not be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our products, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may interrupt our sales efforts, delay

our regulatory approval process in other countries, or impact and limit the type of regulatory approvals our product candidates receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations.

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.

Our research and development activities and our third-party manufacturers’ and suppliers’ activities involve the controlled storage, use, and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling, and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers’ facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our licensors and our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently, and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage.

We are currently conducting and will continue to conduct clinical trials in foreign countries, which could expose us to risks that could have a material adverse effect on the success of our business and the delivery of clinical trial data.*

We have conducted in the past and are currently conducting clinical trials in the United ~~States; Canada; Sydney, Australia; Ankara, Turkey; Hannover, Germany; Karachi, Pakistan; Auckland,~~States, Canada, Australia, Turkey, Germany, Pakistan, New Zealand, Mongolia, Spain, France, Bulgaria, Romania, Taiwan, Sweden, Italy, Belgium, Switzerland, United Kingdom, Greece, Moldova, Ukraine, Russia, and ~~Jerusalem and Beersheba,~~ Israel, and accordingly, we are subject to risks associated with doing business globally, including commercial, political, and financial risks. Emerging regions, such as Eastern Europe, Latin America, Asia, and Africa, as well as more developed markets, such as the United Kingdom, France, Germany, and Australia, provide clinical study opportunities for us. In addition, we are subject to potential disruption caused by military conflicts; potentially unstable governments or legal systems; civil or political upheaval or unrest; local labor policies and conditions; possible expropriation, nationalization, or confiscation of assets; problems with repatriation of foreign earnings; economic or trade sanctions; closure of markets to imports; anti-American sentiment; terrorism or other types of violence in or outside the United States; health pandemics; and a significant reduction in global travel. For example, both Turkey and Pakistan are key regions for clinical activity relating to Hepatitis Delta Virus, and further outbreaks of violence and political instability in the region could disrupt our clinical operations or otherwise limit our ability to access or conduct clinical studies in those regions. Certain countries have closed their borders due to COVID-19 preventing activation of clinical sites. Our success will depend, in part, on our ability to overcome the challenges we encounter with respect to these risks and other factors affecting U.S. companies with global operations. If our global clinical trials were to experience significant disruption due to these risks or for other reasons, it could have a material adverse effect on our financial results.

We or the third parties upon whom we depend may be adversely affected by earthquakes, natural epidemics or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.

~~Our~~Earthquakes, health epidemics or other natural disasters could severely disrupt our operations and have a material adverse effect on our business. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, damaged critical infrastructure, such as the manufacturing facilities of our third-party CMOs, or otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. For example, in December 2019, an outbreak of a novel strain of coronavirus (COVID-19) originated in Wuhan, China. Since certain starting materials of certain of our products obtained from third-party chemical suppliers are manufactured in China and Japan, an outbreak of communicable diseases in the region, or the perception that such an outbreak could occur, and the measures taken by the governments of countries affected, could adversely affect our business, financial condition or results of operations by limiting our ability to manufacture product within or outside for example China, Japan, Italy, Canada, and the United States, forcing temporary closure of facilities that we rely upon or increasing the costs associated with obtaining starting materials and then clinical supplies of our product candidates. The extent to which the coronavirus impacts our results will depend on future developments, which are highly uncertain and cannot be accurately predicted, including new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. In addition, our corporate headquarters ~~are~~is located in the San Francisco Bay Area, which has in the past experienced severe earthquakes and other natural ~~disasters.~~disasters and is currently

experiencing an outbreak of COVID-19. We do not carry earthquake insurance. Earthquakes or other natural disasters could severely disrupt our operations or those of our collaborators, and have a material adverse effect on our business, results of operations, financial condition, and prospects. If a natural disaster, terrorist attack, power outage, or other event occurred that prevented us from using or damaged critical elements of our business and operations (such as the manufacturing facilities of our third-party contract manufacturers) our business may be disrupted for a substantial period of time. We have limited ~~or no~~ disaster recovery and business continuity plans in place currently and our business would be impaired in the event of a serious disaster or similar event. We may incur substantial expenses to develop and implement any disaster recovery and business continuity plans, which could have a material adverse effect on our business.

Our business is currently adversely affected by and could be materially adversely affected in the future by the effects of disease outbreaks, epidemics and pandemics including the evolving effects of the COVID-19 outbreak. We have a significant number of clinical trial sites in countries that have been directly affected by COVID-19. We depend on manufacturing operations for various stages of our supply chain in countries that have been directly affected by COVID-19. COVID-19 continues to adversely affect our business and could materially and adversely affect our operations and those of our manufacturers and other third parties with whom we conduct business.

Our business has been adversely affected by COVID-19 and could be materially and adversely impacted by COVID-19 or other health epidemics in regions where we have significant manufacturing facilities, concentrations of clinical trial sites or other business operations.

The COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting employees, patients, community and business operations, as well as the U.S. economy and financial markets. The effects of shelter-in-place orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.

Additionally, some of our suppliers of certain materials used in the production of our drug products are located in China, Japan, Canada, Italy and the United States. While many of these materials may be obtained by more than one supplier, including suppliers outside of China, Japan, Canada, Italy and the United States, port closures and other restrictions resulting from the coronavirus outbreak in the region may disrupt our supply chain or limit our ability to obtain sufficient materials for our drug products.

In addition, our clinical trials have been and may continue to be affected by the COVID-19 pandemic. Site initiation and patient enrollment has been delayed, due to prioritization of hospital resources toward the COVID-19 pandemic, travel restrictions imposed by governments, and the inability to access sites for initiation and monitoring. In our D-LIVR trial, the COVID-19 pandemic has delayed enrollment in our global clinical trial, some patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services, we may be unable to obtain blood samples for testing, and we may not be able to provide study drug to patients.

Further, as a result of the COVID-19 pandemic, the extent and length of which is uncertain, we may be required to develop and implement additional clinical study policies and procedures designed to help protect study participants from the COVID-19 virus, which may include using telemedicine visits, remote monitoring of patients and clinical sites, and measures to ensure that data from clinical studies that may be disrupted as result of the pandemic are collected pursuant to the study protocol and consistent with GCPs, with any material protocol deviation reviewed and approved by the site Institutional Review Board (IRB). Missed scheduled patient appointments, any interruption in study drug supply, or other consequences that may result in incomplete data being generated during a study as a result of the pandemic must be adequately documented and justified. For example, on March 18, 2020, the FDA issued guidance on conducting clinical trials during the pandemic, which describes a number of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include in the clinical study report (or as a separate document) contingency measures implemented to manage the study, any disruption of the study as a result of the COVID-19 pandemic; a list of all study participants by unique subject identifier and by investigational site that were affected by the COVID-19 pandemic, and a description of how the individual’s participation was altered; and analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from investigational product and/or study, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the study.

Further, the FDA may continue to suspend or delay certain foreign inspections, and the EMA may also, and if there continues to be a suspension or delay in inspections, our product application reviews and potential approvals could be impacted or delayed. In response to the COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities. On March 18, 2020, the FDA announced its intention to temporarily postpone routine surveillance inspections of domestic manufacturing facilities and provided guidance regarding the conduct of clinical trials. Subsequently, on July 10, 2020, the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. In May 2021, the FDA updated its guidance, first published in August 2020, clarifying how it intends to conduct inspections during the COVID-19 pandemic, including how it plans to determine which inspections are “mission critical.” The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a

~~Risks Related~~given geographic area, ranging from mission critical inspections to ~~Celladon’s Historical Business Operations~~

~~We are~~resumption of all regulatory activities. Regulatory authorities outside the ~~subject~~United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic, including providing guidance regarding the conduct of ~~securities class action lawsuits that were filed against Celladon in 2015, and additional securities litigation may be brought against us in~~clinical trials. If global health concerns continue to prevent the future.*

~~In July 2015, following Celladon’s announcements~~FDA or other regulatory authorities from conducting their regular inspections, or impact reviews or other regulatory activities, it could significantly impact the ability of the ~~negative CUPID 2 data~~FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.

While we expect the COVID-19 pandemic to continue to adversely affect our business operations, the extent of the impact on our clinical development and regulatory efforts and the ~~suspension~~value of ~~further research~~ and ~~development activities~~market for our common stock will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ~~subsequent declines~~ultimate duration of the ~~price of its common stock, three putative class actions were filed~~pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. ~~District Court for~~and in other countries, and the ~~Southern District~~effectiveness of ~~California against Celladon~~actions taken globally to contain and ~~certain of its current and former officers. The complaints generally alleged that~~treat COVID-19. In addition, to the ~~defendants violated Sections 10(b) and 20(a)~~extent the evolving effects of the ~~Securities Exchange Act~~ongoing COVID-19 pandemic adversely affects our business and results of ~~1934, as amended, or~~operations, it may also have the ~~Exchange Act, by making materially false and misleading statements regarding the clinical trial program for MYDICAR, thereby artificially inflating the price~~effect of Celladon’s common stock. The complaints sought unspecified monetary damages and other relief, including attorneys’ fees. On December 9, 2015, the district court consolidated the three putative securities class actions and appointed a lead plaintiff to represent the putative class. The lead plaintiff filed a consolidated amended complaint on February 29, 2016.

~~On October 7, 2016, the district court granted defendants’ motion to dismiss the consolidated amended complaint and granted leave to amend within 60 days from the date~~heightening many of the ~~district court’s order. The lead plaintiff subsequently filed a notice of intent not to amend the consolidated amended complaint~~other risks and ~~instead indicated that it intended to appeal the district court’s decision. On December 9, 2016, the district court closed the case.~~

On December 28, 2016, the lead plaintiff filed a notice to the United States Court of Appeals for the Ninth Circuit appealing the district court’s order dismissing the consolidated amended complaint. On May 5, 2017, lead plaintiff filed his opening brief. On July 5, 2017, defendants filed their answering appellate brief.

It is possible that additional suits will be filed, or allegations made by stockholders, with respect to these same or other matters and also naming us and/or our former officers and directors as defendants. We believe that we have meritorious defenses and intend to defend these lawsuits vigorously. Due to the early stage of these proceedings, we are not able to predict or reasonably estimate the ultimate outcome or possible losses relating to these claims. While we and Celladon’s former directors and officers have a separate liability insurance policy dedicated to any claims that may arise from premerger events, there is no assurance that the coverage will be sufficient. In addition, any such litigation could resultuncertainties described elsewhere in ~~substantial costs and a diversion of our management’s attention and resources, which could harm our business.~~this ‘‘Risk Factors’’ section.

The market price of our common stock has been and may continue to be highly volatile, and you may not be able to resell some or all of your shares at a desired market price.

The market price of our common stock has been and is likely to continue to be volatile. Our stock price could be subject to wide fluctuations in response to a variety of factors, including the following:

Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual ~~companies.~~companies, including very recently in connection with the ongoing COVID-19 pandemic, which has resulted in decreased stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. These broad market ~~fluctuations~~and industry factors, including potentially worsening economic conditions and other adverse effects or developments relating to the ongoing COVID-19 pandemic, may also adversely affect the trading price of our common stock.

In the past, following periods of volatility in the market price of a company’s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation.

Effective December 31, 2019, we ceased to be an “emerging growth company,” and the reduced reporting requirements applicable to “emerging growth companies” no longer apply, which has increased our costs as a result of being a public company and places additional demands on management.

Effective December 31, 2019, we ceased to be classified as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act (the JOBS Act). We are now considered an Accelerated Filer and a Smaller Reporting Company, which will require accelerated deadlines of periodic reports. In March 2020, the definition of an Accelerated Filer was amended to exclude Smaller Reporting Companies from the requirements of the Sarbanes-Oxley Act Section 404(b).

We have previously taken advantage of the JOBS Act’s reduced disclosure requirements applicable to “emerging growth companies” regarding executive compensation and exemptions from the requirements of holding advisory say-on-pay votes on executive compensation. Since we are no longer classified as an “emerging growth company,” we are no longer eligible for such reduced disclosure requirements and exemptions and as such, we are required to hold a say-on-pay vote and a say-on-frequency vote at our 2019 annual meeting of stockholders. As a result, we expect that because we are no longer classified as an “emerging growth company,” we will require additional attention from management with respect to our disclosures and will incur increased costs, which could include higher legal fees, accounting fees, consultant fees and fees associated with investor relations activities, among others.

We will incur costs and demands upon management as a result of complying with the laws and regulations affecting public companies.

We have incurred and will continue to incur significant legal, accounting and other expenses associated with public company reporting requirements. We also incur costs associated with corporate governance requirements, including requirements under the Sarbanes-Oxley Act, as well as rules implemented by the SEC and The ~~NASDAQ~~Nasdaq Stock Market LLC. These rules and regulations impose significant legal and financial compliance costs and make some activities more time-consuming and costly. For example, our management team consists of certain executive officers who have not previously managed and operated a public company. These executive officers and other personnel will need to devote substantial time to gaining expertise regarding operations as a public company and compliance with applicable laws and regulations. In addition, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as executive officers, which may adversely affect investor confidence and could cause our business or stock price to suffer.

Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management.

Provisions in our certificate of incorporation and bylaws may delay or prevent an acquisition or a change in management. These provisions include a classified board of directors, a prohibition on actions by written consent of our stockholders and the ability of the board of directors to issue preferred stock without stockholder approval. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the DGCL, which prohibits stockholders owning in excess of 15% of our voting stock from merging or combining with us. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of management.

We do not anticipate that we will pay any cash dividends in the foreseeable future.

We expect to retain our future earnings to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders, if any, for the foreseeable future.

Future sales of shares by existing stockholders could cause our stock price to decline.

If existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after legal restrictions on resale lapse, the trading price of our common stock could decline. Certain of our existing stockholders, including Columbia Threadneedle Investments, 683 Capital Management, BlackRock Institutional Trust, and Vivo Ventures Fund VI, ~~L.P. and Interwest Partners X,~~ L.P., and their respective affiliated entities, own substantial ownership interest in our common stock and any decision to sell a significant number of shares may negatively impact the price of our common stock.

The ownership of our common stock is highly concentrated, and it may prevent stockholders from influencing significant corporate decisions and may result in conflicts of interest that could cause our stock price to decline.

Our executive officers, directors and 5% stockholders and their affiliates beneficially own or control a significant portion of the outstanding shares of our common stock. Accordingly, these executive officers, directors, 5% stockholders and their affiliates, acting as a group, have substantial influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets or any other significant corporate transactions. These stockholders may also delay or prevent a change of control of us, even if such a change of control would benefit our other stockholders. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors’ perception that conflicts of interest may exist or arise.

~~Because the Merger resulted in an ownership change under Section 382 of the Internal Revenue Code our~~Our net operating loss carryforwards and certain other tax attributes are now subject to limitations.

Our federal and state net operating loss (NOL) carry-forwards will begin to expire, if not utilized, beginning in 2030 for federal income tax purposes and 2028 for California state income tax purposes. These NOL carry-forwards could expire unused and be unavailable to offset future income tax liabilities. Under legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, as modified by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), U.S. federal net operating loss carryforwards generated in tax years beginning after December 31, 2017 may be carried forward indefinitely but, in the case of tax years beginning after December 31, 2020, may only be used to offset 80% of taxable income annually. In addition, California recently enacted A.B. 85 which imposed limits on the usability of California state net operating losses and certain tax credits in tax years beginning after 2019 and before 2023. Such limitations could result in the expiration of portions of our net operating loss and tax credit carryforwards before utilization. Moreover, if a corporation undergoes an ~~“ownership change”~~ownership change within the meaning of Section 382 of the ~~Internal Revenue~~ Code ~~of 1986, as amended, or Section 382,~~(Section 382) the corporation’s ~~net operating loss~~NOL carryforwards and certain other tax attributes arising from before the ownership change are subject to limitations on use after the ~~ownership~~“ownership change.” In general, an ownership change occurs if there is a cumulative change in the corporation’s equity ownership by certain stockholders that exceeds fifty percentage points over a rolling three-year period. Similar rules may apply under state tax laws. ~~The recent Merger~~Our merger with Celladon resulted in such an ownership change and, accordingly, ~~both parties’ net operating loss~~Celladon’s NOL carryforwards and certain other tax attributes will be subject to further limitations on their use. WeIn addition, we assessed whether Eiger had an ownership change, as defined by Section 382 of the Code, as a result of the Merger and other stock issuances that occurred from our formation through December 31, ~~2016.~~2020. Based upon this assessment, ~~no reduction was~~we have experienced ownership changes on April 20, 2016, October 18, 2018 and December 31, 2020. Due to these ownership changes, reductions were made to ~~the federal~~our NOL and ~~state NOL carryforwards or federal and state~~ tax credit carryforwards under these rules. Additional ownership changes in the future could result in additional limitations on ~~the combined organization’s~~our net operating loss and tax credit carryforwards. Consequently, even if we achieve profitability, we may not be able to utilize a material portion of our ~~net operating loss~~NOL carryforwards and other tax attributes, which could have a material adverse effect on cash flow and results of operations. A full valuation allowance has been provided for the entire amount of our remaining net operating losses.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned thereunto duly authorized.

Delaware		33-0971591
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

~~350 Cambridge Ave, Suite 350~~2155 Park Boulevard Palo Alto, CA		94306
(Address of Principal Executive Offices)		(Zip Code)

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock (par value $0.001 per share)	EIGR	The Nasdaq Stock Market LLC

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐ ~~(Do not check if a smaller reporting company)~~☒	Smaller reporting company	☒
Emerging growth company	☒☐

		Page No.
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements:		3
Condensed Consolidated Balance Sheets as of September 30, ~~2017~~2021 (unaudited) and December 31, ~~2016~~2020		3
Condensed Consolidated Statements of Operations for the three and nine months ended September 30, ~~2017~~2021 and ~~2016~~2020 (unaudited)		4
Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, ~~2017~~2021 and ~~2016~~2020 (unaudited)		5
Condensed Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, 2021 and 2020 (unaudited)		6
Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, ~~2017~~2021 and ~~2016~~2020 (unaudited)		68
Notes to the Condensed Consolidated Financial Statements (unaudited)		79
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		1522
Item 3. Quantitative and Qualitative Disclosures About Market Risk		2232
Item 4. Controls and Procedures		2232

PART II. OTHER INFORMATION
Item 1. Legal Proceedings		2333
Item 1A. Risk Factors		2333
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		4767
Item 3. Defaults Upon Senior Securities		4767
Item 4. Mine Safety Disclosures		4867
Item 5. Other Information		4867
Item 6. Exhibits		4968
Signatures		5069

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
Options to purchase common stock		1,530,394		1,124,044		1,530,394		1,124,044
Warrants to purchase common stock		10,180		10,180		10,180		10,180
Total		1,540,574		1,134,224		1,540,574		1,134,224

	September 30, 2017								September 30, 2021
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Financial assets:
Money market fund	$	8,016	$	—	$	—	$	8,016
Money market funds									$	42,394	$	—	$	—	$	42,394
Corporate debt securities		—		13,031		—		13,031		—		40,787		—		40,787
Commercial paper		—		8,233		—		8,233
U.S. government bonds										—		30,357		—		30,357
Total	$	8,016	$	21,264	$	—	$	29,280	$	42,394	$	71,144	$	—	$	113,538

	Shares			Weighted- Average Grant Date Fair Value
Unvested shares as of December 31, 2020		37,500		$	6.95
Granted		611,500		$	8.76
Vested		(33,750	)	$	6.35
Forfeited		(1,875	)	$	9.99
Unvested shares as of September 30, 2021		613,375		$	8.78

Undiscounted lease payments	September 30, 2021
Remaining in 2021	$	162
2022		662
2023		113
2024		1
Total undiscounted payments		938
Less: imputed interest		54
Present value of future lease payments		884
Less: current portion of operating lease liabilities		608
Operating lease liabilities	$	276

	Payments due by period
	Total		Less than 1 year		1 – 3 Years		3 – 5 Years		More than 5 years
Operating lease obligations (1)	$	401	$	330	$	71	$	—	$	—
Term loan debt (2)	$	15,000	$	—	$	12,083	$	2,917	$	—
Interest on term loan debt (3)	$	4,378	$	979	$	2,205	$	1,194	$	—
Total	$	19,779	$	1,309	$	14,359	$	4,111	$	—

Exhibit Number		Description of Document

3.1		Amended and Restated Certificate of Incorporation of Celladon Corporation (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K of Celladon Corporation, filed with the SEC on February 10, 2014).

3.2		Amended and Restated Bylaws of Celladon Corporation (incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K, filed with the SEC on February 10, 2014).

3.3		Certificate of Amendment of Amended and Restated Certificate of Incorporation of Celladon Corporation (incorporated by reference to Annex D to the Registration Statement on Form S-4, as amended (File No. 333-208521), originally filed with the SEC on December 14, 2015).

3.4		Certificate of Amendment of Amended and Restated Certificate of Incorporation of Celladon Corporation (incorporated by reference to Annex E to the Registration Statement on Form S-4, as amended (File No. 333-208521), originally filed with the SEC on December 14, 2015).

~~31.1~~10.1**		~~Certification~~Offer Letter Agreement, by and between Eiger BioPharmaceuticals, Inc. and Erik Atkisson, dated as of ~~Principal Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a)~~August 26, 2021.

~~31.2~~10.2**		Amendment No. 6 to Loan and Security Agreement, dated October 6, 2021, by and between Eiger BioPharmaceuticals, Inc. and Oxford Finance LLC.

31.1**		Certification of Principal Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a).

31.2**		Certification of Principal Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a).

32.1+		~~Certification~~Certifications of Principal Executive Officer and Principal Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350).

~~101.INS~~101.INS**		Inline XBRL Instance ~~Document~~Document- the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

~~101.SCH~~101.SCH**		Inline XBRL Taxonomy Extension Schema Document

~~101.CAL~~101.CAL**		Inline XBRL Taxonomy Extension Calculation Linkbase Document

~~101.DEF~~101.DEF**		Inline XBRL Taxonomy Extension Definition Linkbase Document

~~101.LAB~~101.LAB**		Inline XBRL Taxonomy Extension Label Linkbase Document

~~101.PRE~~101.PRE**		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, has been formatted in Inline XBRL.

	Eiger BioPharmaceuticals, Inc.

Date: November ~~9, 2017~~4, 2021	By:	/s/ David A. Cory
		David A. Cory
		Director, President and Chief Executive Officer
		(Principal Executive Officer)

	Eiger BioPharmaceuticals, Inc.

Date: November ~~9, 2017~~4, 2021	By:	/s/ ~~James Welch~~Sriram Ryali
		~~James Welch~~Sriram Ryali
		Chief Financial Officer
		(Principal Financial Officer)